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Our society’s population is ageing rapidly. Nowadays, more than 15% of the Dutch 
population, 2.5 million persons, is aged 65 years and over and this is expected to 
increase to 25% in 2040. (1) Unfortunately, not all of these older subjects spent their 
life in good health. To strive for high quality cure and care for these “complex” older 
people, knowledge of and research in these aged persons is essential. On the one hand, 
increasingly data become available that the physiological processes in the oldest old 
subjects may be distinct from those in young and middle-aged individuals. Therefore, 
to extrapolate research findings, validated in large studies done with selected younger 
individuals, into the older populations can be misleading. On the other hand, some 
organs are les affected than others by the ageing process. For example renal function 
decreases linearly with increasing age, however there is limited effect of increasing age 
on bone marrow capacity.
This thesis focuses on the physiological aspects of the interesting triad renal function, 
erythropoietin production and haemoglobin levels at old age. The decrease in renal 
function is one of the most relevant functional defects that occurs with increasing age. 
Erythropoietin (EPO) is produced within the kidney. Furthermore, EPO is the hormone 
that regulates red blood cell production. Red blood cells develop in the bone marrow 
and circulate for about 100–120 days in the body. Haemoglobin is the iron-containing 
oxygen-transport protein within the red blood cells and with increasing age haemoglo-
bin seems to remain stable. Therefore lower haemoglobin levels are not “normal” at old 
age with increased morbidity and mortality as a result. To develop treatment strategies 
in the very old, research into the physiology of ageing is needed in population based 
studies of older subjects. In this thesis we focus on physiological aspects as well as 
on consequences of decreased renal function and the impact of changes in EPO and 
haemoglobin levels at old age.
Renal function at old age
A decrease in renal function is one of the most important functional defects that occurs 
with increasing age. Kidney function is stable until age 30 to 40 and then declines linearly 
at an average rate of about 8ml/min/1.73m2 per decade. (2) Although in clinical practice, 
the glomerular filtration rate (GFR) is considered to be the best overall reflection of renal 
function, it cannot be measured easily in daily clinical practice. Therefore GFR is usu-
ally estimated from equations (eGFR) such as the classic Cockroft-Gault formula (C-G) 
(3) and the Modification of Diet and Renal Disease equation (MDRD). (4) More recently 
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the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) was sug-
gested as a more accurate estimate of GFR, especially for the relative high ranges of 
eGFR. (5-7) However, none of these measures are well validated in large samples of older 
populations. Moreover, impaired renal function has important clinical implications since 
it has been associated with increased cardiovascular complications and all cause and 
cardiovascular mortality. (8,9)
Erythropoietin
Erythropoietin (EPO) is primarily produced in the kidney and is the principle regulator 
of red blood cell production. (10) Decreased oxygen availability in the kidney, due to 
for example anemia or renal hypoperfusion, triggers the production of erythropoietin 
within the kidney. Conflicting data are available concerning EPO levels at old age. On 
the one sight it has been suggested that the availability of the kidney to secrete EPO 
declines with ageing and as a consequence anemia in older subjects is attributed to the 
decreased levels of erythropoietin. (11) On the other hand, the limited available stud-
ies suggest that erythropoietin levels of older subjects are comparable with those of 
younger individuals. (12,13) Whether endogenous erythropoietin levels are inadequate 
or nearly normal in elderly is important in clinical practice, because of therapeutic 
decision making about administrating exogenous erythropoietin for the correction of 
anemia.
Haemoglobin
Anemia, defined as low(er) haemoglobin levels (14), is a common clinical condition in 
the elderly (15,16) and with advancing age associated with unfavourable events like 
functional dependency, cardiovascular events, cognitive decline and impaired survival. 
(17-20) Anemia at old age is not simply a result of diminished hematopoiesis, since there 
is only little effect of ageing on bone marrow function. (21) Iron deficiency and chronic 
renal failure are the most common causes of anemia in older subjects. Other well known 
causes in clinical practice for anemia are folate and vitamin B12 deficiency. Furthermore, 
several epidemiological studies have found that up to 30% of anemia cases in the older 
population is unexplained, even when extensive clinical information is available. (22-
24) Nowadays, this type of anemia is classified as “unexplained anemia”. The underlying 
pathophysiological mechanisms of unexplained anemia have yet to be established and 
it’s clinical relevance for older subjects needs to be determined.
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Introduction
1Aim and outline of this thesis
In this thesis physiological aspects of the triad haemoglobin, renal function and eryth-
ropoietin at very old age are described. Furthermore, the prognostic consequences of 
changes in haemoglobin, renal function and erythropoietin in a cohort of oldest old 
subjects is assessed.
Chapter 2 presents the results of calculating renal function in old age by using three 
different formulae: Cockroft-Gault, MDRD and CKD-EPI equation and to find the best 
estimate of GFR (eGFR) at old age. The haematopoietic capacity at old age was studied 
in chapter 3 in two independent, population-based cohorts as well as the relationship 
between haemoglobin and mortality in oldest old subjects was investigated. The effect 
of increasing age on renal function and serum levels of haemoglobin and erythropoietin 
(EPO) in randomly selected individuals in the range of 30-100 years was described in 
chapter 4. Since high erythropoietin levels have been shown to predict the risk of death 
among patients with chronic heart failure, in chapter 5 the prognostic value of elevated 
erythropoietin levels on mortality among very elderly people in the general popula-
tion was assessed. In chapter 6 the independent predictive value of clinical markers of 
inflammation in relation to mortality, both vascular and nonvascular, was studied in very 
old participants, since there predictive value have already been shown in middle-aged 
populations. Given that in approximately 30% of older persons with anemia, the cause 
of the anemia is unexplained, in chapter 7 we assessed the clinical differences between 
older subjects with explained and unexplained anemia and investigated whether these 
subjects have different mortality patterns compared to subjects without anemia.
Finally, in chapter 8 is assessed whether higher haemoglobin levels predict length of 
hospital stay after hip fracture surgery in elderly subjects. The goal of treating anaemia 
in older patients who have undergone hip fracture surgery is to enhance functional 
recovery. In chapter 9 the findings and the possible clinical implications of all presented 
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Performance of Cockroft-Gault, MDRD and 
CKD-EPI in estimating prevalence of renal function 
and predicting survival in the oldest old
JM Willems, LT Vlasveld, WPJ den Elzen, RGJ Westendorp, 
TJ Rabelink, AJM de Craen, GJ Blauw




Introduction The question for prevalence estimation and validation of the various 
eGFRs in old age is still under debate. To assess renal function with increasing age, we es-
timated mean eGFR, in subjects aged 20-85 years. Furthermore, we assessed prevalence 
of eGFR in a population-based sample of 85 year olds and investigated the performance 
of these eGFRs in predicting mortality in the oldest old.
Methods Renal function with increasing age was assessed in subjects aged 20-85 years 
from the Bronovo Study Cohort. We estimated prevalences of eGFRs and mortality risks 
in a population-based study of persons aged 85 years and older, the Leiden 85-plus 
Study. The GFRs were estimated by three different formulas.
Results After the age of 70 years, the C-G tended to give relatively lower eGFRs. An eGFR 
< 60 was found in 90% of the subjects aged 85 years as calculated by C-G, in 55% of the 
subjects using MDRD and in 68% of the 85 year old subjects as calculated by CKD-EPI. 
When renal function was <30 ml/min/1.73m2, an increased mortality risk was observed 
by C-G (HR 1.9 (95% CI 1.1-3.3)), by MDRD (HR 3.5 (95% CI 1.8-6.7)), whereas by CKD-EPI 
significance was not reached (HR 2.4 (95% CI 0.9-6.4)).
Conclusion Our study demonstrates that in subjects above age 70, C-G gives lower 
estimates of renal function when compared to MDRD and CKD-EPI. Furthermore, preva-
lence of renal dysfunction (CKD stage 1-3) at age 85 years was highest for C-G (90%), 
lowest for MDRD (55%), and 68% for CKD-EPI. Moreover, we found that in subjects aged 
85 years MDRD predicted mortality best.
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Introduction
Chronic kidney disease (CKD) coinciding with impaired renal function is predominantly a 
disease of the elderly and is associated with an increased risk for all cause and cardiovas-
cular mortality, even after controlling for known risk factors. (1,2) Furthermore, renal im-
pairment also affects safety of many common drugs used in older people. The glomular 
filtration rate (GFR) is considered to be the best overall reflection of renal function, but is 
not easily measured in daily practice. Therefore creatinine clearance is usually assessed 
by the classic Cockroft-Gault formula (C-G) and an estimate of glomerular filtration rate 
is often calculated by the Modification of Diet and Renal Disease equation (MDRD). 
(3,4) More recently the Chronic Kidney Disease Epidemiology Collaboration equation 
(CKD-EPI) has been suggested as a more accurate estimate of eGFR (5), especially in the 
relative high ranges of eGFR (CKD stage 1 and 2). (6,7) However, these measures have 
not been used to assess the impact of eGFR on truly estimating renal function in older 
populations, and they are not well validated in the elderly. Since it is difficult to measure 
GFR in a large population based group of old people, the question of prevalence estima-
tion and validation of the various eGFRs in this age group is still unanswered.
Compared to the MDRD and CKD-EPI estimates of GFR, an important characteristic of 
the C-G formula is the inclusion of total body weight in the equation, as a reflection of 
muscle mass, the main determinant of creatinine generation. (3) With increasing age, 
body composition changes with decreasing muscle mass and increasing fat tissue as 
characteristic features, resulting in decreased lean body mass in very old age. (8,9) These 
age related changes might have important effects on creatinine clearance as calculated 
by the C-G formula in older individuals. In contrast to the classic C-G formula, the MDRD 
and CKD-EPI equations incorporates body surface area, resulting in eGFRs per 1,73 m2 
body surface area.
Since it is virtually impossible to validate the various eGFRs in large population based 
samples of oldest old people by measuring GFR, for example by creatinine or inulin 
clearance, it is of great importance to determine the best measure of GFR in older 
people. First, to assess renal function with increasing age, we estimated mean creatinine 
clearance by C-G, and eGFR by MDRD and CKD-EPI equations, in 10 year age groups of 
subjects aged 20-85 years. Then, we estimated prevalence of eGFR in a population-based 
sample of 85 year olds and investigated the performance of these eGFRs in predicting 





To investigate renal function as calculated by the C-G, MDRD and CKD-EPI equations, a 
cohort of subjects aged 20 to 85 years was used (study 1). This cohort was originally es-
tablished to set reference values for laboratory measurements for various age categories 
in the Bronovo Hospital, The Hague, The Netherlands (10,11), a general hospital affiliated 
with Leiden University Medical Center, Leiden, the Netherlands. There were no inclusion 
criteria. Exclusion criteria were pregnancy, diabetes mellitus, use of oral contraceptives, 
vitamin- or iron supplements, and oral anti-coagulants. From all participants a venous 
blood sample was drawn. The Medical Ethical Committee of Bronovo Hospital accorded 
the study and all participants provided informed consent to study participation.
For studying prevalence of renal dysfunction based on the three formulas and their 
performance in predicting all cause mortality, the population of the Leiden 85-plus 
Study was used (study 2). The Leiden 85-plus Study is a population-based prospective 
follow-up study of persons aged 85 years and older. There were no selection criteria 
other than age. At baseline, all individuals were living in Leiden, The Netherlands. A total 
number of 599 subjects (response rate 87%) agreed to participate. (12) All participants 
were visited at their place of residence where interviews took place, height and weight 
measurements were done and venous blood samples were drawn. After inclusion all 
subjects were followed for mortality until February 2009.The Medical Ethical Committee 
of the Leiden University Medical Center (LUMC) approved the study and all participants 
provided informed consent for study participation.
Laboratory measurements
All blood samples were collected in sterile EDTA tubes. Plasma creatinine concentrations 
were determined in the Bronovo Hospital (study 1) with Synchron LX-20, Beckman Coul-
ter and in the LUMC (study 2) according to the Jaffe method using Hitachi 747, Tokyo, 
Japan.
Creatinine clearance and Glomular Filtration Rate equations
Three equations for renal function were used in our analysis (Table 1): the Cockcroft-
Gault formula (C-G) (3), the four variable Modification of Diet in Renal Disease equation 
(MDRD) (4), and the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-
EPI). (5)
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Table 1. Formulas of C-G, MDRD and CKD-EPI
Gender Serum creatinine* eGFR (ml/min/1.73m2)
Cockroft-Gault Female All ((140- age) x bodyweight / serum creatinine) x 0.85
Male All (140- age) x bodyweight / serum creatinine
MDRD Female All 175 x (serum creatinine/88.4)−1.154 x age−0.203 x 0.742
Male All 175 x (serum creatinine/88.4)−1.154 x age−0.203
CKD-EPI Female ≤ 62 144 x (serum creatinine/88.4/0.7)−0.329 x (0.993)age
Female > 62 144 x (serum creatinine/88.4/0.7)−1.209 x (0.993)age
Male ≤ 80 141 x (serum creatinine/88.4/0.7)−0.411 x (0.993)age
Male > 80 141 x (serum creatinine/88.4/0.7)−1.209 x (0.993)age
*Serum creatinine is stated in μmol/L.
Abbreviations; eGFR: estimated glomerular filtration rate; MDRD: modification of diet in renal disease formula; CKD-
EPI: chronic kidney disease epidemiology equation.
Because all our individuals were of the Caucasian race the multiplier factor for race was not applied.
Chronic Kidney Disease
CKD was defined according to the K/DOQI staging. (13) CKD stage 3 has been sub-
divided into 30-44 (stage 3a) and 45-59 ml/min/1.73m2 (stage 3b) as there is evidence of 
graded increase in mortality risk (Table 2). (14,15)
Table 2. Stages of chronic kidney disease
GFR CKD stage Description
≥ 60 Stage 1 and 2 Kidney damage with normal or mildly decreased GFR
45-59 Stage 3a Moderately decreased GFR
30-44 Stage 3b Moderately decreased GFR
< 30 Stage 4 and 5 Severely decreased GFR or kidney failure
Adapted from K/DOQI clinical practice guidelines (13)
GFR is stated in ml/min/1.73m2
CKD stage 3 has been sub-divided into 30-44 (stage 3b) and 45-59 ml/min/1.73m2 (stage 3a) as there is evidence of 
graded increase in mortality risk (9,14)
Mortality
Mortality data of the Leiden 85-plus Study (study 2), recorded between the start of 
the study, 1 September 1997, and 1 February 2009, were obtained from the municipal 
registry, which are publicly available. For the deceased participants the cause of death 
was obtained from Statistics Netherlands. We obtained permission to collect this data 




Data are presented as number (percentages) for clinical characteristics and as median 
(interquartile range) for continuous parameters. The association between measures of 
renal function and mortality was analyzed with sex-adjusted Cox proportional hazard 
models. Differences in laboratory measurements between the different categories of 
eGFR as well as between sexes were determined by Mann-Whitney tests. SPSS software 
(version 16.0.1, SPSS Inc, Chicago, Ill) was used for statistical analyses. P-values lower 
than 0.05 were considered statistically significant.
Results
Creatinine clearance and eGFR in subjects aged 20-85 years
Characteristics of subjects in study 1 are reported in Table 3. The study sample com-
prised 242 subjects, 125 (52%) women and 117 (48%) men.














Female, n (%) 23 (55) 22 (51) 23 (54) 25 (50) 23 (56) 9 (43)
Creatinine (µmol/L) 76 (71-87) 85 (74-91) 82 (72-97) 86 (74-99) 83 (74-93) 87 (76-97)
Cockroft-Gault (ml/min) 117 (97-127) 112 (95-138) 97 (82-112) 87 (77-96) 78 (68-85) 57 (52-82)
MDRD (ml/min/1.73m2) 94 (85-102) 86 (77-92) 78 (72-87) 75 (66-84) 72 (66-82) 69 (58-77)
CKD-EPI (ml/min/1.73m2) 104 (93-111) 93 (83-99) 82 (75-92) 78 (68-87) 71 (65-83) 65 (54-73)
Data presented are as median (IQR), unless otherwise stated.
Abbreviations: MDRD; Modification of Diet in Renal Disease equation, CKD-EPI; Chronic Kidney Disease Epidemiology 
Equation.
In subjects aged 21 to 30 years, mean creatinine clearance as calculated by Cockroft-
Gault formula was 117 ml/min, mean eGFR by MDRD formula was 94 ml/min/1.73m2 
and by CKD-EPI equation was 104 ml/min/1.73m2. In the oldest age category, 71- 85 
years, creatinine clearance calculated by Cockroft-Gault formula was 57 ml/min, eGFR 
by MDRD formula 69 ml/min/1.73m2 and by CKD-EPI equation 65 ml/min/1.73m2. With 
increasing age, a significant decline of renal function was observed in C-G, MDRD and 
CKD-EPI (all p<0.01). Figure 1 shows estimates of mean renal function as assessed with 
C-G, MDRD and CKD-EPI in the age categories. The three lines of the C-G, MDRD, and 
CKD-EPI cross at age 70 years. Before the age of 70 years, renal function as assessed by 
C-G is above the MDRD and CKD-EPI, indicating that before age 70 years eGFR assessed 
with the C-G formula tends to give relatively higher eGFRs. 
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After the age of 70 years, the line of the renal function as assessed with the C-G formula 
is below the MDRD and CKD-EPI, indicating that after age 70 years, eGFRs assessed with 
the C-G formula tend to give relatively lower eGFRs.
Prevalence of renal dysfunction in the oldest old
Characteristics of subjects in study 2 are reported in Table 4. Sixty-seven percent of the 
subjects was female and 30% had no comorbid illness. Median weight of all subjects 
was 69.5 kg and the median body mass index (BMI) was 26.7 kg/m2. Median creatinine 
clearance, calculated by C-G, was 43 ml/min. Using this formula, in 496/550 subjects 
(90%) a creatinine clearance lower than 60 ml/min was found. Furthermore, of these 85 
years old subjects, the median eGFR, as calculated by MDRD, was 58 ml/min/1.73m2 and 
1
Figure 1. Renal function in subjects of different age categories. Modification of Diet in Renal Disease 
(MDRD) clearance and Chronic Kidney Disease Epidemiology Collaboration clearance (CKD-EPI) are 






















Figure 2. Proportion of subjects in the various categories of eGFRs, calculated by C-G, MDRD and CKD-EPI. 
Abbreviations: C-G; Cockroft-Gault formula, MDRD; Modification of Diet in Renal Disease, CKD-EPI; Chronic 
Kidney Disease Epidemiology Collaboration clearance.
Chapter 2
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308/562 subjects (55%) were having an eGFR lower than 60 ml/min/1.73m2. Moreover, 
when calculating GFR by CKD-EPI formula, a median eGFR of 53 ml/min/1.73m2 was 
found and in 383/562 subjects (68%) eGFR was under 60 ml/min/1.73m2.
We determined the proportion of subjects in the various categories of renal function, 
calculated by C-G, MDRD and CKD-EPI. Figure 2 illustrates that the C-G estimates result 
in higher prevalences of renal failure compared to MDRD and CKD-EPI.
Reclassification of subjects in the various eGFR categories assessed by MDRD and CKD-
EPI is shown in Table 5. When the MDRD formula was used, 308/562 (54.8%) subjects 
were labelled as CKD stage 3 or worse (eGFR< 60 ml/min/1.73m2). When the CKD-EPI 
Table 4. Characteristics of subjects aged 85 of the Leiden 85-plus Study
n=562
Female 377 (67)
Comorbid illness 398 (70)
Institutionalized 104 (18)
MMSE 26 (22-28)
Weight (kg) 69.5 (61.5-78.3)
Length (cm) 159 (154-166)
Body Mass Index (weigth/m2) 26.7 (24.2-29.9)
Body Surface Area (m2)* 1.72 (1.61-1.85)
Serum Creatinine (µmol/L) 92 (81-108)
Cockroft-Gault (ml/min)∫ 43 (37-51)
>60 ml/min 54 (10)
30-60 ml/min 454 (83)
<30 ml/min 42 (7)
MDRD (ml/min/1.73m2) 58 (49-68)
>60 ml/min/1.73m2 254 (45)
30-60 ml/min/1.73m2 298 (53)
<30 ml/min/1.73m2 10 (2)
CKD-EPI (ml/min/1.73m2) 53 (46-62)
>60 ml/min/1.73m2 179 (32)
30-60 ml/min/1.73m2 365 (65)
<30 ml/min/1.73m2 18 (3)
Continuous parameters are presented as median (IQR).
Categorial data are presented as number (%)
*Body Surface Area = calculated by DuBois’s formula
∫ in 12 subjects weight was not available to calculate Cockroft-Gault clearance
Abbreviations: MMSE; Mini Mental State Examination, MDRD; Modification of Diet in Renal Disease, CKD-EPI; Chronic 
Kidney Disease Epidemiology Collaboration clearance.
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formula was used, 383/562 (68.1%) subjects were classified as CKD stage 3 or worse. 
Overall, 92 subjects moved up one CKD stage when MDRD was used in stead of CKD-
EPI. There were no subjects that moved up when CKD-EPI was used in stead of MDRD. 
The largest reclassification was for the subjects within the CKD-EPI category 30-59 ml/
min/1.73 m2. Of the 365 subjects within this category, 75 were reclassified into the MDRD 
category 60-89 ml/min/1.73 m2.
The associations between the different eGFRs and mortality risk are shown in Table 6. 
For the calculations of the mortality risk, eGFRs above 60 ml/min/1.73 m2 were set as 
reference group. With the C-G formula, an almost twofold increased risk for all-cause 
mortality was found for subjects with a renal function lower than 30 ml/min/1.73m2 (HR 
1.9 (95% CI 1.1-3.3)). An increased mortality risk was also observed by calculating renal 
function by MDRD, when renal function was under 30 ml/min/1.73m2 (HR 3.5 (95% CI 
1.8-6.7), and when renal function was between 30-44 ml/min/1.73m2 (HR 1.6 (95% CI 
1.2-2.2). When renal function was estimated with CKD-EPI, subjects with renal function 
Table 5. Number of subjects in categories of CKD assessed by MDRD and CKD-EPI
CKD-EPI MDRD
<15 15-29 30-59 60-89 >90
<15 2 0 0 0 0 2
15-29 0 8 8 0 0 16
30-59 0 0 290 75 0 365
60-89 0 0 0 170 9 179
>90 0 0 0 0 0 0
Total 2 8 298 245 9 562
Numbers in bold indicate those subjects who do not change CKD category on the basis of eGFR assessed with 
MDRD and CKD-EPI. Italic figures indicate the numbers of subjects who change into a different CKD stage.
MDRD and CKD-EPI clearance are stated in ml/min/1.73m2.
Abbreviation: CKD; Chronic Kidney Disease, MDRD; Modification of Diet in Renal Disease, CKD-EPI; Chronic Kidney 
Disease Epidemiology Collaboration clearance.
Table 6. Relative mortality risks in categories of eGFR for C-G, MDRD and CKD-EPI
Hazard ratio (95% CI)
< 30 ml/min 30-44 ml/min 45-59 ml/min >60 ml/min
C-G 1.9 (1.1-3.3)* 1.3 (0.9-1.9) 1.0 (0.7-1.5) 1
MDRD 3.5 (1.8-6.7)** 1.6 (1.2-2.2)** 1.1 (0.9-1.3) 1
CKD-EPI 2.4 (0.9-6.4) 1.3 (0.9-1.8) 1.1 (0.9-1.5) 1
All hazard ratios are adjusted for sex.
C-G clearance is in ml/min, MDRD and CKD-EPI clearance is in ml/min/1.73m2.
Abbreviations: C-G; Cockcroft-Gault, MDRD; Modification of Diet in Renal Disease, CKD-EPI; Chronic Kidney Disease 
Epidemiology Collaboration clearance.
*=P<0.05, ** P≤ 0.01 compared to the reference group (>60 ml/min).
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lower than 30 ml/min/1.73m2 had a similar increased all-cause mortality risk compared 
to MDRD, but significance was just not reached, HR 2.4 (95% CI 0.9-6.4).
Discussion
The results of our study are threefold. First, our study demonstrates that in subjects un-
der age 70 years, C-G gives higher estimates of renal function when compared to MDRD 
and CKD-EPI, while in subjects above age 70, C-G gives lower estimates of renal function 
when compared to MDRD and CKD-EPI. Second, prevalence of renal dysfunction (CKD 
stage 3-5) at age 85 years was highest for C-G (90%), lowest for MDRD (55%), and 68% for 
CKD-EPI. Third, we found that in subjects aged 85 years MDRD predicted mortality best. 
These results suggest that at very old age the MDRD formula might be the best estimate 
for eGFR, since the MDRD formula is most discriminative in predicting mortality.
eGFR in various age categories
We showed that C-G, MDRD and CKD-EPI formula provide different estimates of renal 
function in various age categories. Under the age of 70, C-G clearance relatively over-
estimated renal function compared to eGFRs calculated by both MDRD clearance and 
CKD-EPI, whereas above the age of 70 creatinine clearance assessed with C-G formula 
resulted in relatively lower values. Our results are in line with earlier studies with older 
individuals (all mean age <85 years) (16,17), and also comparable with another commu-
nity based study with younger participants (mean age of 75 years). (18) The difference 
in mean age of the participants is the most plausible explanation between these study 
findings. 
The discrepancy in renal function calculated by the C-G formula and the MDRD and 
CKD-EPI equations may be explained by the intrinsic design of the estimates. In com-
parison with the MDRD and CKD-EPI equations, in the C-G formula the body weight is 
included next to the creatinine and age. In old age, lean body mass is reduced secondary 
to both sarcopenia and to increasing fat tissue. (8,9) The MDRD and CKD-EPI equations 
are adjusted for body surface area (BSA) (19), resulting in an eGFR value per 1.73 m2 
BSA. Therefore, ageing may also have an effect on this adjusted eGFR since, next to the 
changes in body weight, both women and men loose height with increasing age, result-
ing in a decline in BSA in old age. (20) In the Leiden 85-plus Study mean BSA was 1.72 
m2, suggesting that the BSA adjustment used in the MDRD and CKD-EPI estimates may, 
however, be appropriate in this very old population. It may be questioned whether it is 
appropriate to index the C-G formula for BSA, because weight is already included in the 
equation as a variable. Therefore, the use of the C-G formula in clinical practice for very 
old individuals is questionable.
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eGFR in the oldest old
Recently, the CKD-EPI, has been introduced in clinical practice, because of the possible 
inadequacies of the C-G and MDRD equations. (4,5) Our study shows that implementa-
tion of the CKD-EPI formula has consequences for very old subjects. Above the age of 
70, eGFR calculated by CKD-EPI formula is underestimating renal function in comparison 
with eGFR calculated by MDRD, although not as much as the C-G formula. Compared 
with the classic C-G equation, introduction of the CKD-EPI formula will lower the amount 
of older individuals with CKD. Whereas based on these results, implementation of CKD-
EPI formula would raise the number of older individuals with CKD on the basis of eGFR 
estimated with the MDRD formula, with as a consequence more hospitalizations, costs 
and also other therapeutic implications. 
A recently published large population based study of over a half million UK people of all 
ages (21) found that introduction of the CKD-EPI formula would reduce the prevalence 
of CKD in subjects < 70 years, but would raise the prevalence of CKD in the over 70 year 
old group. Furthermore, another report with particular emphasis of eGFR and the effect 
of age found that among the very elderly CKD-EPI may actually increase CKD prevalence 
estimates. (22) 
Although there are several studies with younger individuals that suggest that the CKD-
EPI equation more accurately categorizes individuals (5,7) and although the US National 
Kidney Foundation has already recommended the adoption of the CKD-EPI formula for 
routine eGFR reporting by laboratories in the USA (23), based on our results and others 
(21,22,24-26), more research in the older individuals is warranted, before the CKD-EPI 
can be implemented in clinical practice for the oldest old age categories, in order to pre-
vent unnecessary diagnostic procedures, therapeutic interventions and medical costs.
Mortality risks and eGFR at old age
Since one goal of estimating renal function in clinical practice is to obtain estimates of 
deaths risk in various stages of CKD, it seems logical to use the equation that provides 
the best prediction of these outcome, especially in older individuals. (1,2) Therefore, we 
examined the association between the three different assessment methods for renal 
function and mortality in old age and found the MDRD equation to be best predictive 
for mortality. Subjects with MDRD < 45 ml/min/1.73m2 had higher mortality risks com-
pared to renal function calculatd by C-G or CKD-EPI formulae. Moreover, in subjects with 
creatinine clearance < 30 ml/min/1.73m2 calculated by MDRD formula, a 3.5 increased 
risk of mortality was found. 
Our findings are in contrast with a large Italian study of 942 community dwelling sub-
jects. (18) The participants of this study, the InCHIANTI study, had a mean age of 75 years. 
They found that only the C-G and not the MDRD equation was predictive for mortality. 
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Since estimating equations C-G and MDRD both incorporate age in the formula, a 
plausible explanation for the discrepancy between findings of the two studies is the 
difference in mean age of the participants. In our study we only included oldest old 
subjects, all aged 85 years. However, a study with hospitalized older individuals in the 
Netherlands (mean age 78 year) showed results similar to ours. (27) Furthermore, in 
line with our findings, a large British cohort study of people aged 75 years and older, 
showed a increased mortality risk with MDRD < 45 ml/min/1.73m2. (15) Data of very old 
community-dwelling very subjects (≥ 85 years) and the prediction of all cause mortality 
by C-G and especially MDRD and CKD-EPI formulae are scarce.
Strong points and limitations
This is one of the few studies evaluating the effect of three different estimation methods 
for renal function in very old individuals in a population-based setting with a very high 
participation rate (87%) and with complete follow-up. This permits us to generalize our 
conclusions to very old people in the general population at large. Unfortunately, in 
both study cohorts, we did not have 24-hour urine collections for the measurement of 
creatinine clearance, although accuracy of urine collection at home done in a very old 
study population can be discussed. Moreover, accurate GFR measurements using inulin 
or iothalamate infusions are undoable for large scale study populations.
Conclusion
In conclusion, estimation of renal function in very old persons can be facilitated by GFR 
equations, although C-G, MDRD and CKD-EPI all have their own limitations. We found 
that after age 70 years, C-G gives lower eGFRs and might therefore overestimating the 
number of individuals having CKD in comparison with both MDRD and CKD-EPI after the 
age of 70 years. Moreover, our results suggest that the MDRD formula might be the best 
estimate for eGFR in the oldest old followed by the CKD-EPI formula, since the MDRD 
formula is the best in predicting mortality. Our study suggests that implementation of 
CKD-EPI formula would raise the number of older individuals with CKD in comparison 
with the MDRD formula, with consequences for therapeutic decision making procedures 
and resulting in more referrals to nephrologists. Therefore, more research in older indi-
viduals is urgently needed, before the CKD-EPI can be implemented in clinical practice 
for the oldest old age categories.
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Haematopoietic capacity and exceptional survival  
The Leiden Longevity Study
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Introduction Anemia has been associated independently of underlying diseases, with
increased mortality in older persons. Furthermore, it has previously been demonstrated 
that nonagenarian siblings from the Leiden Longevity Study are genetically enriched 
for longevity. We questioned whether genetic enrichment for survival is dependent on 
sustained normal hematopoietic capacity in old age.
Methods Prospective follow-up study of two independent, population-based cohorts; 
the Leiden Longevity Study and the Leiden 85-plus Study. From the Leiden Longevity 
Study 1001 nonagenarians with familial longevity were included. As age-matched con-
trols 260 nonagenarians without longevity were used from the Leiden 85-plus Study. 
Hematological measurements like haemoglobin, leucocytes, and thrombocytes were 
performed for all subjects with and without familial longevity. Standardised mortal-
ity ratios, linear regression and left censored Cox regression were used for statistical 
analysis. 
Results Mortality in nonagenarians with familial longevity was 28 % lower than in 
nonagenarians from the general population (SMR 0.72, 95%CI 0.65-0.79, p<0.001). No 
differences were found between haemoglobin, leucocyte and thrombocyte count in no-
nagenarians with and without familial longevity (all p>0.3). Nonagenarians with familial 
longevity had greater mortality risk when anemia was present (sex adjusted hazard 
ratio 1.78, 95% CI 1.47-2.16, p<0.001). No relationship was found between leucocytes, 
thrombocytes, and mortality in either study group (all p>0.2).
Conclusion Haematopoietic capacity cannot explain the significant better survival of 
nonagenarians with familial longevity, but in those with familial longevity, anemia may 
contribute to mortality.
33
Haematopoietic capacity and exceptional survival
3
Introduction
The incidence of anemia rises sharply with age, with reported prevalences of up to 40% 
in octagenerians. (1) There are two possible explanations for anemia in elderly people. 
First, anemia can be a result of diminished hematopoiesis, although there is limited ef-
fect of increasing age on bone marrow capacity. (2) Second, anemia can be a reflection 
of concurrent disease, but in several population-based studies, anemia has been associ-
ated independently of underlying diseases, with increased mortality in older persons. 
(3) Studies of relationships of leucocytes and thrombocytes with lifespan have shown 
inconsistent results. (4)
Previous studies have consistently indicated that genetic factors can explain approxi-
mately 25% of the variation in lifespan. (5-7) It has previously been demonstrated that 
nonagenarian siblings from the Leiden Longevity Study are genetically enriched for 
longevity. (8) Twin studies have shown that haematological parameters have a strong 
genetic component, indicating that genetic factors explain 37%, 62%, and 57% of the 
variance in haemoglobin, leucocytes, and thrombocytes. (9,10) The question is whether 
genetic enrichment for survival is dependent on sustained normal hematopoietic ca-
pacity in old age.
In the Leiden Longevity Study, there was a unique opportunity to assess whether hae-
matological parameters in nonagenarians are associated with higher mortality risks and 
whether nonagenarians with familial longevity have higher serum levels of haemoglo-
bin, leucocytes and thrombocytes than age-matched population controls.
Methods
Study populations
All study subjects with familial longevity came from long-living families in the Nether-
lands. A representative example of a pedigree of a family of the Leiden Longevity Study 
is shown in Figure 1. A family could participate if at least two siblings were long-living. 
There were four inclusion criteria for the elderly subjects with familial longevity: men had 
to be 89 years or older and women had to be aged 91 and older, there had to be at least 
one living brother or sister who fulfilled the first criterion and was willing to participate, 
the siblings had to have the same biological mother and father, and the parents of the 
sibling pairs had to be Dutch and Caucasian. In total over 450 sibships and their offspring 
and spouses were included and venous blood samples were drawn. All were recruited 




Figure 1. Representative pedigree of the Leiden Longevity Study. The black symbols show the ascertained 
long-living subjects and the grey symbols represent their offspring. P1, F1 and F2 represent the three 
generations included in the study.
A population control group of similar age for the long-living familial nonagenarians was 
constructed from the nonagenarians of the Leiden 85-plus Study. The Leiden 85-plus 
Study is a prospective, population based follow-up study of persons aged 85 years and 
older without familial longevity. At baseline, all individuals were living in Leiden, The 
Netherlands; 599 subjects participated. All participants were visited at their place of resi-
dence where interviews took place and a venous blood sample was drawn. All subjects 
used in our analysis were followed from age 90 onwards for mortality.
Because the probability of reaching the age of 90 in the Netherlands is 0.5%, hypotheti-
cally three subjects would overlap in both study cohorts, but in practice only two sub-
jects were overlapping. The Medical Ethical Committee of the Leiden University Medical 
Center (LUMC) approved both studies, and all participants provided informed consent 
for study participation.
Laboratory measurements
Blood samples were collected in sterile ethylenediaminetetraaceteric acid tubes. Mea-
surements of haemoglobin, leucocytes, and thrombocytes for the subjects with familial 
longevity were performed in the Leiden Medical Diagnostical Center (SCAL) with the 
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automated system Siemens ADVIA 1200 system (SMSD, Tarrytown, NY). For the subjects 
without familial longevity the haematological measurements were done in the Leiden 
University Medical Center with the fully automated Sysmex XE-2100 system 
(TOA Medical Electronics, Kobe, Japan). Quality assurance indicated that there were no 
differences between the laboratories in the levels of haemoglobin and the leucocytes, 
but, thrombocyte counts were 3% higher in the SCAL and 2% lower in the LUMC than in 
the general Dutch population. Therefore, thrombocyte values were standardized to the 
Dutch population mean before the analysis. 
Anemia was defined according to the criteria of the World Health Organization. (11) The 
normal reference interval for haemoglobin concentration defined at 7.5 to 10.0 mmol/L 
(120-160 g/L) for women and at 8.1 to 11.2 mmol/L (130-180 g/L) for men. Leucopenia 
was defined as absolute number of leucocytes less than 4.0 x 109/L and thrombopenia 
was defined as absolute number of thrombocytes less than 150 x 109/L.
Statistical analysis
The statistical analysis proceeded in various stages. First, the mortality of the nonage-
narians with familial longevity was compared with that of the general Dutch popula-
tion using standardized mortality ratios (SMRs). The SMR is the ratio of the observed 
number of deaths in the study relative to the expected number of deaths calculated 
from the mortality rates from the general population, adjusted for sex, age distribution, 
and calendar period. Second, the mortality of the subjects with familial longevity was 
compared with that of the subjects without familial longevity using left- censored Cox 
regression adjusted for sex. Third, sex-specific cross-sectional analysis of differences in 
haemoglobin, leucocyte, and thrombocyte counts of long-living elderly people and 
elderly people without familial longevity of the Leiden 85-plus Study was done with 
linear regression adjusted for age. Fourth, all subjects were classified as anemic, leu-
copenic, or thrombopenic according to the criteria of the World Health Organisation. 
The association between anemia, leucopenia, and thrombopenia in nonagenarians with 
and without familial longevity was assessed with left-censored Cox regression and was 
visually depicted using a Kaplan-Meier survival curve. Standardised mortality ratios and 
left-censored Cox regression were calculated using STATA, version LP 9.0 (Stata Corp, 
College Station, TX). All other analyses were performed with SPSS for Windows (version 
12.0.1, SPSS Inc., Chicago,Ill).
Results
The study sample of nonagenarians with familial longevity of the Leiden Longevity 
Study comprised 622 women and 379 men. The age matched population controls with-
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out familial longevity of the Leiden 85-plus Study comprised 188 women and 72 men 
(Table 1).
Mortality risk of the nonagenarians with familial longevity of the Leiden Longevity Study 
and of the general Dutch population in 2005 is visually depicted in Figure 2. The stan-
dardised mortality ratio for all 1001 nonagenarians with familial longevity compared 
with that of the general population was 0.72 (95% confidence interval (CI) = 0.65- 0.79), 
indicating 28% lower mortality in the study sample than the general Dutch population. 
For the familial long-living women from the Leiden Longevity Study, the standardised 
mortality ratio was 0.70 (95% CI = 0.62- 0.79). For the familial long-living elderly men the 
standardised mortality ratio was 0.74 (95% CI= 0.63-0.87).
The overall relative mortality risk of the nonagenarians with familial longevity compared 
with that of the control nonagenarians of the Leiden 85-plus Study was 0.61 (95% CI = 
0.49-0.75). The mortality risk did not change after excluding subjects who were institu-
tionalized 0.63 (95% CI = 0.48-0.90).
Hematological characteristics of nonagenarians with and without familial longevity are 
shown in Table 2. No differences were found between the mean hemoglobin, leucocyte, 
and thrombocyte concentrations of the female and male nonagenarians with and 
without familial longevity. For all subjects, the difference in hemoglobin, leucocytes and 
thrombocytes was not significant (all p > 0.5).
Subjects with familial longevity had an increased risk for all-cause mortality when they 
were anemic (sex-adjusted relative risk 1.71, 95% CI = 1.47-2.07, p<0.001). The greater risk 
Table 1. Characteristics of nonagenarians with and without familial longevity stratified according to sex.













Age, mean (SE) 93.3 (0.1) 90 (0) <0.001 91.8 (0.1) 90 (0) <0.001
Institutionalized, n (%) NA 16 (9) - NA 9 (13) -
Follow-up, years, mean (SE) 2.7 (1.3) 2.1 (0.9) - 2.5 (1.3) 2.5 (1.7) -
Haemoglobin, mmol/L, mean (SE) 8.1 (0.1) 8.2 (0.1) 0.08 8.4 (0.1) 8.1 (0.1) 0.10
Leucocytes, x109/L, mean (SE) 7.1 (0.1) 6.8 (0.2) 0.20 7.8 (0.4) 7.1 (0.9) 0.51
Thrombocytes, x109/L, mean (SE) 241 (2.6) 244 (4.6) 0.53 220 (3.8) 218 (7.1) 0.76
* Subjects recruited from the Leiden Longevity Study
¶ Subjects recruited from the Leiden 85-plus Study
Abbreviations: SE: standard error; NA: not available.
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for mortality was even more pronounced in the non-familial nonagenarians with anemia 
(sex-adjusted relative risk 2.16, 95% CI = 1.54-3.02, p<0.001) (Figure 3). The p-value for 
the difference in hazard ratios between studies was 0.24. When haemoglobinwas ana-
lyzed as a continuous variable in the analysis, a hazard ratio of 0.74 (95% CI = 0.68-0.82, 
p<0.001) was found per unit increase in haemoglobin in the familial longevity subjects. 









































































































Figure 2. Mortality rates in elderly with familial longevity of the Leiden Longevity Study and the general 
Dutch population in women and men.
Table 2. Relationship between anemia, leucopenia, and thrombocytopenia and mortality in 
nonagenarians with and without familial longevity.
Familial longevity* No familial longevity¶
Haematological parameters Hazard Ratio
(95% Confidence Interval) P-value
Anemia 1.71 (1.41-2.07) <0.001 2.16 (1.54-3.02) <0.001
Leucopenia 1.49 (0.88-2.52) 0.14 1.12 (0.49-2.53) 0.79
Thrombopenia 1.39 (0.97-1.99) 0.07 0.82 (0.44-1.53) 0.55
* Subjects recruited from the Leiden Longevity Study
¶ Subjects recruited from the Leiden 85-plus Study
Hazard ratios are age and sex adjusted.
Chapter 3
38
Leucopenia and thrombopenia were present in a low percentage in both sexes of the 
long-living nonagenarians (< 7 %), and there was no association of leucopenia and 
thrombopenia with mortality risk (all p > 0.1) (Table 2).
Discussion
These results indicate that nonagenarian men and women with familial longevity have 
better survival compared to age-matched elderly people from the general population. 
No differences were found in haemoglobin level, leucocyte, and thrombocyte count 
between subjects with and without familial longevity. It was also found that familial 
long-living elderly men and women with anemia had higher mortality than subjects 
with normal levels. For leucopenia and thrombopenia, no greater mortality risk was 
found.
The better survival of elderly people with familial longevity of the Leiden Longevity 
Study than of the elderly subjects from the general Dutch population was in line with 
expectations. Earlier analysis of family members of this exceptional cohort of long-lived 
individuals already suggested a clear survival advantage. (8) When following the mem-
bers of this cohort, a significantly lower mortality risk was found than in age-matched 
controls from the Leiden 85-plus study.
No significant differences were foung in serum haemoglobin levels in members of fami-
lies with familial longevity compared to population controls in both men or women. If 
Figure 3. Graphical representation of the relationship between anemia and mortality from age 90 
onwards in subjects with and without familial longevity.
39
Haematopoietic capacity and exceptional survival
3
higher haemoglobin levels had caused the better survival of elderly people with familial 
longevity, a difference in mean haemoglobin level between the two populations in both 
generations would have been expected. Therefore, hemoglobin levels are unlikely to ex-
plain the greater survival of subjects with familial longevity. It is likely that factors other 
than haemoglobin level genetically enriched the participants of the Leiden Longevity 
Study for better survival.
Elderly subjects with familial longevity had almost twice the mortality risk when they 
were anemic than non-anemic subjects in both sexes. This association between anemia 
and mortality has been studied before. These studies have also shown an association 
between anemia and greater mortality in elderly men and women without familial 
longevity. (3,12-14) Although subjects with and without familial longevity had similar 
levels of haematological parameters, the effect of these parameters can be differential. 
As shown in Table 2, the risks for mortality due to anemia were greater in both study 
groups, but the hazard ratio for mortality was more pronounced in subjects without 
familial longevity. Because of these greater mortality risks in all anemic elderly subjects, 
haemoglobin levels below normal are a reason for further clinical investigation in medi-
cal practice and may not be considered simply a result of “normal aging”.
No significant differences in leucocyte and thrombocyte counts were found in the fami-
lies with familial longevity and their population controls in men or women. Moreover, 
no greater mortality risk was found in subjects of familial longevity with leucopenia or 
thrombopenia. These data are at odds with the limited reported literature on mortal-
ity risk and white blood cell count or platelet count. One study showed that leucocyte 
count was an independent risk factor for all-cause mortality. (15) The study subjects 
were adults with a mean age of 56.7 years and of Asian origin. No recent literature was 
found about blood platelet count and mortality in elderly subjects. One article reported 
an association with low platelet count and mortality in middle-aged men with a mean 
age of 50. (16) This study is therefore not comparable with that of the current study.
Although the prevalence of anemia was 24% in the elderly women and approximately 
40% in the elderly men with familial longevity, the prevalence of thrombopenia and leu-
copenia was far less in either of the sexes (2-7%). Previous studies have also shown little 
effect of aging on human bone marrow function. (2,17) Therefore, it is likelythat long-
living subjects, have the same bone marrow reserve capacity as population controls. 
The reported heritability estimates for haemoglobin, leucocytes, and thrombocytes 
of respectively 0.37, 0.62, and 0.57, respectively, also indicate that haemoglobin levels 
are more volatile and that anemia therefore reflects underlying morbidity more than 




The strength of the current study was that it compared two cohorts of the oldest-old: 
one group of nonagenarians with familial longevity and one cohort resembling the 
general elderly population, all in relative large numbers.
A possible limitation of this study is that the possibility of selection bias cannot be 
excluded. Conditions associated with poor outcome, such as diseases at baseline, living 
conditions, and cognition, could not be compared in either study population, although 
the mortality risk did not change when institutionalized elderly subjects were excluded.
Conclusion
In conclusion, nonagenarian men and women with familial longevity have better sur-
vival than age-matched elderly from the general population. No differences were found 
in haemoglobin level, leucocyte and thrombocyte count between elderly with and 
without familial longevity. It was found that all long-living elderly people anemia had 
higher mortality than subjects with normal level; therefore haemoglobin levels below 
normal are a reason for further clinical investigation in medical practice. No greater mor-
tality risk was found for leucopenia and thrombocytopenis. Therefore, haematopoietic 
capacity cannot explain the significant better survival of nonagenarians with familial 
longevity, and lower haemoglobin levels may reflect concurrent disease.
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Stable haemoglobin and increasing 
erythropoietin levels despite age related 
renal dysfunction





Introduction Lower haemoglobin levels in old age are believed to be caused by a 
decline in production of erythropoietin (EPO) by age-related renal dysfunction. On the 
other hand, there is some evidence that EPO levels remain stable with advancing age 
or even increase. We investigated the association between increasing age and serum 
levels of haemoglobin, EPO and renal function in healthy individuals in different age 
categories.
Methods The Bronovo Study cohort consists of 268 healthy individuals in the range 
of 30-100 years, living in The Hague, the Netherlands. In this observational study, hae-
moglobin, reticulocytes, erythrocytes and EPO measurements were performed for all 
subjects. Jonckheere Terpstra test was used for statistical analysis.
Results With increasing age there was no significant change in median haemoglobin 
(p-trend = 0.06) and erythrocyte count (p-trend = 0.06), while median reticulocyte 
count significantly decreased over time (p-trend = 0.01). MDRD clearance significantly 
decreased from the youngest age group to the oldest age category (p-trend < 0.001). 
Furthermore, there was a significant increase in EPO levels with increasing age (p-trend 
< 0.001).
Conclusion The findings of this study suggest that erythrocyte count and haemoglobin 
level remain stable througout live, whereas a decrease of the reticulocyte count was 
observed with increasing age. Furthermore, an increase in EPO level was found despite 
age related renal function loss. Two possible hypothesis are described. Nevertheless, 
further studies are needed to elucidate the mechanisms behind the observed increase 
of erythroipoietin and the maintenance of haemoglobin levels and erythrocyte counts 
in older persons.
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Introduction
In old age, anaemia is believed to be caused by a decline in production of erythropoietin 
by age-related renal dysfunction. (1-3) Furthermore, it has been suggested that the abil-
ity of the kidney to secrete erythropoietin in response to tissue hypoxia declines with 
increasing age. (4) On the other hand, there is some evidence that erythropoietin levels 
in older subjects are similar to those of younger individuals. (5) Furthermore, one longi-
tudinal study, in a cohort of 143 healthy adults aged 38-82 years without chronic kidney 
disease, found that erythropoietin concentration increases with advancing age. (6) We 
investigated the association between increasing age and serum levels of haemoglobin, 




From a study cohort, originally established to set reference values for various laboratory 
measurements for different age categories in the Bronovo Hospital, The Hague, The 
Netherlands, all persons aged 30 to 100 years were used for the current analysis. (7) 
The 275 subjects were consecutively enrolled into the study; 160 (58%) persons were 
employees from the Bronovo hospital, 41 (15%) subjects were living in nursing homes in 
The Hague and 74 (27%) persons were retrieved from the outpatient services from dif-
ferent general practitioners in The Hague. No inclusion criteria were applied. Exclusion 
criteria were pregnancy, diabetes mellitus, the use of oral contraceptives, vitamin- or 
iron supplements and oral anti-coagulants. From all participants a venous blood sample 
was drawn. The Medical Ethical Committee of Bronovo Hospital accorded the study and 
all participants provided informed consent for study participation.
Laboratory measurements
Haemoglobin, Mean Corpuscular Volume (MCV), erythrocyte, leucocyte, thrombocyte 
and reticulocyte count were measured on a LH750, Beckman Coulter Brea, Ca, USA. 
Serum EPO levels were measured using enzyme immunoassay (EIA), Immulite 2500, 
Siemens Medical Diagnostics, Tarrytown, NY, which has a sensitivity of 1.2 mU/ml and 
a coefficient of variation less than 6%. Creatinine was measured on a Synchron LX-20, 
Beckman Coulter. Creatinine clearance was estimated with the Modification of Diet in 
Renal Disease equation (MDRD).2 Folic acid and vitamin B12 were determined in one 





Differences in parameters over age categories were tested with Jonckheere Terpstra 
tests. Correlations between the various parameters were tested with Spearman’s cor-
relation coefficients. SPSS software (version 16.0.1, SPSS Inc, Chicago, Il) was used for 
all statistical analyses. P-values lower than 0.05 were considered statistically significant.
Results
Characteristics of study subjects in the various age groups are shown in Table 1. The 
study sample comprised 268 subjects, 141 (53%) women and 127 (47%) men. Median 
EPO level for subjects aged > 90 years was 12.4 mIU/ml, for subjects aged 76-90 years it 
was 12.5 mIU/ml, and for subjects in the younger age categories erythropoietin levels 
varied between 9.5 and 11.1 mIU/ml. The median haemoglobin level in subjects aged > 
90 years was 7.9 mmol/L in all other age groups it was 8.7-8.8 mmol/L. Mean Corpsular 
Volume (MCV) was 91 fL in the subjects aged > 90 years and ranged between 90 and 93 
fL in subjects in the other age catergories. Erythrocyte count for subjects age > 90 years 
was 4.2 x 109/L and for subjects age < 90 years erythrocyte count varied between 4.6 
and 4.7 x 109/L. Reticulocyte count was 7.3% in the oldest age category and increased to 
11.3 % in the youngest age category. Renal function, calculated by MDRD formula, was 
64 ml/min/1.73m2 in the oldest age category and 85 ml/min/1.73m2 in the youngest age 
category.











Female, n (%) 33 (52) 40 (52) 25 (54) 18 (53) 5 (50)
Erythropoietin (mIU/ml) 9.5 (8.1-11.5) 9.7 (7.9-12.7) 11.1 (8.7-13.7) 12.5 (9.9-15.7) 12.4 (11.8-14.5)
Haemoglobin (mmol/L) 8.8 (8.3-9.3) 8.7 (8.2-9.4) 8.8 (8.5-9.2) 8.7 (7.7-9.2) 7.9 (7.6-8.3)
Erythrocyte (x 109/L) 4.7 (4.3-4.9) 4.6 (4.3-4.9) 4.6 (4.4-4.8) 4.6 (4.3-4.8) 4.2 (4.0-4.7)
Reticulocytes (%) 11.3 (7.3-13.9) 11.5 (8.1-15.3) 8.7 (7.3-12.5) 8.6 (7.7-12.5) 7.3 (5.5-10.3)
Creatinine (µmol/L) 83 (74-91) 86 (71-99) 83 (74-93) 89 (75-100) 98 (81-106)
MDRD (ml/min/1.73m2) 85 (76-90) 76 (68-84) 73 (66-82) 66 (55-74) 64 (47-66)
Data presented are as median (IQR), unless otherwise stated.
Abbreviations: MDRD; Modification of Diet in Renal Disease equation.
A significant increase in EPO levels was found with increasing age (p-trend < 0.001) 
(Figure 1). Furthermore, with increasing age there was no significant change in median 
haemoglobin (p-trend = 0.06) and erythrocyte count (p-trend = 0.06), while median 
reticulocyte count significantly decreased over time (p-trend = 0.01). MDRD clearance 
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significantly decreased from the youngest age group to the oldest age category (p-
trend < 0.001). However, no significant difference between the different age categories 
was found for MCV, leucocyte or thrombocyte counts, or for folic acid and vitamin B12 
levels (data not shown). Moreover, a significant correlation between erythropoietin level 
and reticulocyte count, p=0.012, was found.
Discussion
The most important finding in our study is the maintenance of haemoglobin levels and 
erythrocyte counts throughout life. Furthermore, we found that with increasing age 
reticulocyte count decreases and EPO levels increase.
These findings are comparable with an earlier French report (8) demonstrating that 
haemoglobin level and erythrocyte count are preserved at the same level during life. 
Furthermore, they found a significant lower reticulocyte count in people older than 
65 years compared to younger individuals, while the EPO level increases at older age. 
Moreover, other reports showed that EPO levels tend to increase with age despite a 
decline in renal function. (3,6) Furthermore, in a large sample of community dwelling 










































































































Figure 1. Erythropoietin, hemoglobin, reticulocyte levels and MDRD over age categories. All values are 
medians (IQR). P-values between the different age-categories were determined by Spearman’s correlation 
coefficient, where the age-category 30-45 years was set as reference category (* P < 0.05). P-trend was 
calculated with Jonckheere Terpstra test.
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failure (creatinin clearance of < 30 ml/min) had a significantly higher prevalence of 
anemia and significant lower erythropoietin levels. (4)
Although we found that reticulocyte count significant decreases, the total erythrocyte 
count remains stable with advancing age. This apparently conflicting phenomenon 
seems primarily to occur in order to maintain a stable haemoglobin level. There are sev-
eral potential hypotheses (Figure 2). In our first hypothesis EPO has a central role. EPO, 
produced in the renal cortex, is an anti-apoptotic agent for the erythrocytic progenitors 
and after binding to the EPO-receptor it promotes the proliferation and differentiation of 
these cells to pro-erythroblasts and normoblasts through phosphorylation of a intracel-
lular tyrosine-kinase pathway. (9) In addition, EPO protects newly formed erythrocytes 
from destruction resulting in a increased life span of these circulating cells. (10,11) The 
observed maintenance of a stable erythrocyte count during life despite a decrease of the 
reticulocytes may be explained by a prolongation of the erythrocyte survival time. This 
prolongation is most likely due to the observed increase in the EPO level. The question 
arises why increased EPO levels do not result in a sustained reticulocytosis. Therefore, it 
may be hypothesized that with increasing age haematopoietic stem cell become less 
responsive to EPO with diminished erythropoiesis. (12) This imminent anaemia leads 
to an increase in EPO production, but is inappropriate to overcome the diminished 
erythropoiesis. Due to the EPO-induced prolongation of the red cell survival the total 
erythrocyte count remains stable. In this first hypothesis the EPO increase is a secondary 
event and occurs despite an age-related decline in the renal function.
less renal blood 
flow due to 
atherosclerotic 
process 








   











haematopoietic      
stem cell ageing negative feedback 
Figure 2. Possible pathophysiological mechanism as result of ageing kidney
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Alternatively, it may be arqued that primarily EPO increases due to age-related local ath-
erosclerosis within the kidney. (9) Because of the EPO-induced prolongation of the red 
cell survival, erythropoiesis must be down-regulated in order to maintain a stable eryth-
rocyte count. Although it has been stated that after binding of EPO to the EPO-receptor, 
with subsequent activation of the erythroblasts, the EPO-receptor is downregulated. 
Clinical data indicate that continuous exposure to EPO does not lead to a decline in the 
reticulocyte count. (13,14)
Conclusion
In summery, in our first hypothesis EPO rises in order to compensate a diminished eryth-
ropoiesis and therefore prevent an imminent anaemia while in our second hypothesis 
erythropoiesis physiologically declines in order to avoid EPO-induced erythrocytosis. 
Nevertheless, irrespective of the underlying homeostatic mechanism, the events lead 
to stable erythrocyte count and haemoglobin level throughout life. Further studies are 
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White blood cell count and C-reactive protein are 
independent predictors of mortality  
in the oldest old
JM Willems, S Trompet, GJ Blauw, RGJ Westendorp, AJM de Craen




Introduction White blood cell (WBC) count is, like C-reactive protein (CRP), a clinical 
marker of inflammation and predicts cardiovascular disease and mortality in middle 
aged populations. Limited data exist on the association between white blood cell count 
and mortality in the oldest old. Moreover, because CRP and WBC count are closely linked, 
it is not known whether WBC count and CRP are independent risk factors for mortality. 
We assessed the independent predictive value of WBC count and CRP levels in relation 
to mortality, both vascular and non-vascular, in very old subjects.
Methods A total of 599 women and men were evaluated longitudinally in the Leiden 
85-plus Study. Blood samples and medical information were collected at age 85 and all 
subjects were visited annually until age 90 or death. Mortality risks were estimated with 
Cox-proportional hazard models.
Results Increasing WBC count was associated with an increased risk for all cause mortal-
ity (HR (95% Confidence Interval, CI) = 1.26 (1.15-1.38)) after adjustment for sex and 
smoking status. CRP levels were also associated with an increased risk for mortality (HR 
(95%CI) = 1.22 (1.10-1.35)). The association between increasing WBC count and mortal-
ity remained significant after adjustment for CRP levels (HR (95%CI) = 1.20 (1.09-1.33)), 
whereas also the relation between increasing CRP levels and mortality remained signifi-
cant after adjustment for WBC count (HR (95%CI) = 1.17 (1.05-1.30)).
Conclusion Our results suggest that WBC count and CRP levels both independently 
predict mortality in the oldest old.
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Introduction
White blood cell (WBC) count is a marker of systemic inflammation. Elevated levels of 
WBC count are associated with increased risk for morbidity and mortality in middle-aged 
populations. (1-13) Most studies have shown an independent association between high 
WBC count and increased risk for coronary heart disease and cerebrovascular events 
(1-3,7,11) and an increased risk for vascular mortality. (4-6,8-10,13) Only one study has 
shown that elevated WBC count was associated with increased non-vascular mortality. 
(12) Limited data exist on the association between WBC count and mortality in the old-
est old.
Over the past decade C-reactive protein (CRP) has been shown to be a strong marker 
of systemic inflammation and a good predictor of vascular events and mortality. (14-
17) Therefore, in clinical practice, CRP levels are nowadays considered to be a valuable 
marker of low-grade inflammation to predict mortality. Because the relation between 
WBC count and CRP levels has not been studied in detail (18), it is unknown whether 
by indentifying subjects with high levels of CRP, also subjects with high WBC count are 
identified. Moreover, it is also not known whether WBC count and CRP levels predict 
mortality independent of each other.
We investigated whether WBC count and CRP level are independent risk indicators for 
all-cause, vascular, and non-vascular mortalities in the oldest old, using a large popu-
lation-based cohort of subjects aged 85 years who were followed for mortality over a 
period of almost 10 years.
Methods
Study population
The Leiden 85-plus Study is a prospective population-based cohort study of inhabit-
ants of Leiden, The Netherlands. Between September 1997 and September 1999, all 
inhabitants of Leiden born between 1912 and 1914 (n=705) were contacted within a 
month after their 85th birthday. A total of 599 individuals (response rate 87%) agreed 
to participate (19). All participants were visited at their place of residence by medical 
staff and nurses. During this visit a structured face-to-face interview was conducted, a 
venous blood sample was obtained, and an electrocardiogram was recorded. The Medi-
cal Ethical Committee of the Leiden University Medical Center approved the study, and 




All participants were visited annually until age 90 or death. After age 90 the popula-
tion was followed up for mortality until February 2008 (censor date February 11, 2008). 
From the deceased participants the cause of death was obtained from the Dutch Central 
Bureau of Statistics. Only the primary cause of death on the death certificate was used 
in our analyses.
The International Statistical Classification of Diseases (ICD) codes used for vascular 
mortality are I00-I99. For non-vascular mortality all ICD codes except I00-I99 were used.
WBC cell count and CRP measurements
Of 562 participants hematological measurements like WBC count, hemoglobin, and 
thrombocytes were done at the time of recruitment at the Leiden University Medical 
Center with the fully automated system Sysmex XE-2100, TOA Medical Electronics, Kobe, 
Japan. The normal reference interval for the WBC count was set at 4.0 to 10.0 x 109/L. 
EDTA plasma was stored at −80°C. After recruitment, CRP was measured in one batch 
using the dual count solid phase no-boil assay (Diagnostic products Corp, Los Angeles, 
California).
Comorbid illness
Participants without comorbidity (good health status) were defined as having an ab-
sence of a history of stroke, myocardial infarction, diabetes mellitus, malignancy, chronic 
obstructive pulmonary disease, Parkinson’s disease, dementia, hip fracture and arthritis 
at baseline. Arthritis was considered present when the medical history was positive for 
rheumatoid arthritis, osteo-arthritis or polymyalgia rheumatica. Presence of comorbid 
illnesses was obtained from participants’ general practitioners by a semi-structured 
interview and by inspection of computerized records obtained from participants’ 
pharmacies. (20) For participants living in a nursing home, the nursing home physician 
provided the necessary information. Apart from the medical records, diabetes, Parkin-
son’s disease and chronic obstructive lung disease were also considered present when 
specific diabetes medication, anti-Parkinson drugs, or anti-asthmatics were prescribed. 
Furthermore, an electrocardiogram (ECG) was recorded and transmitted to a central ECG 
core laboratory where conventional interpretation was provided. Undiagnosed myocar-
dial infarction was defined as the presence of a Q-wave myocardial infarction on the ECG 
that was unknown to the subject’s general practitioner or nursing home physician. (21)
Statistical analyses
Since CRP levels were not normally distributed, CRP values were first log-transformed. 
Standardized values (per 1 SD increase) were used for comparability between the haz-
ard ratios (HRs) from WBC and CRP. We assessed the standardized values by calculating 
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Z-scores. To calculate the Z-score we used the formula: (individual observation mean 
of study population)/ standard deviation study population. All associations of WBC 
and CRP separately were done with Cox proportional hazards model where WBC and 
CRP were entered as continuous variables in the models which were adjusted for sex, 
institutionalization and smoking status (Model 1). Model 2 includes both WBC and CRP 
levels together entered as a continuous variable , also adjusting for sex, institutionaliza-
tion and smoking status. Hazard ratios (HR) were graphical depicted and indicate the 
change in risk by one standard deviation (SD) increase in WBC count or in CRP level. The 
interaction between WBC and CRP was assessed in one model with both WBC and CRP 
entered as continuous variables along with a cross-product term of the two continuous 
variables. The SPSS software (version 16.0.1, SPSS Inc, Chicago, Il) was used for all statisti-
cal analyses. P-values lower than 0.05 were considered statistically significant.
Results
Table 1 shows the baseline characteristics of the participants. Sixty-six percent of the 
participants were woman, 27% had no comorbidity, and 16% was a current smoker. The 
mean level of WBC count was 6.6 x 109/L. A total of 16 participants (3%) had a WBC 
count less than 4.0 x 109/L, 16 participants (3%) had a WBC count above 10.0 x 109/L. 
The mean CRP level was 7.6 mg/L, 85 participants (15%) had a CRP levels higher than 
the reference value of 10 mg/L. During the mean (SD) follow-up of 5.4 (3.1) years, a total 
of 452 (80%) participants died. Of those, 169 participants died of vascular mortality and 
277 participants died of non-vascular mortality. From six participants the primary death 
cause was not known.
There was no significant association between sex and WBC (p=0.19), nor sex and CRP 
(p=0.08). Because there was a small difference in mortality rate between the sexes we 
nevertheless corrected for sex in all analyses.
The association between WBC count and CRP levels is shown in Table 2. Here, we show 
that the percent of participants who have concordant WBC/CRP tertiles is 45% (the 
diagonal in the table). The percent of the participants whose WBC tertile is lower than 
their CRP tertile is 26% and the percent whose WBC tertile is more than their CRP tertile 
is 29%. The correlation coefficient between WBC and CRP levels is 0.27.
The results of the association of WBC count and levels of CRP with mortality risks are 
shown in Figure 1. With an increase of one SD in WBC count we found a 1.26 (95% CI = 
1.15-1.38) increased risk for all-cause mortality. Similar increased mortality risks were 
Chapter 5
58
observed for both vascular mortality (HR (95%CI) = 1.33 (1.18-1.51)) and non-vascular 
mortality (HR (95%CI) = 1.20 (1.05-1.37)) (Figure 1a). Furthermore, with an increase of 






 Female, n (%) 87 (79) 285 (63)
 Institutionalized, n (%) 10 (9) 93 (21)
 Smoking status, n (%)
  Never smoker
  Former smoker







 No comorbidity*, n (%) 39 (36) 112 (26)









 White blood cells (x109/L) 6.3 (1.4) 6.7 (2.3)
 C-reactive Protein (mg/L) 4.0 (4.3) 8.4 (22.5)
 Cholesterol status
  Total cholesterol (mmol/L)
  Triglycerides (mmol/L)
  HDL (mmol/L)









Data are presented in mean (SD), unless otherwise stated.
Abbreviations: BMI, Body Mass Index; HDL, High Density Lipoprotein; LDL, Low Density Lipoprotein.
* No comorbidity: no history at baseline of stroke, myocardial infarction, hypertension, hypercholesterolemia, diabetes 
mellitus, malignancy, chronic obstructive pulmonary disease, Parkinson’s disease, dementia, hip fracture or arthritis.
# LDL was calculated from total cholesterol, triglycerides and HDL levels.
Table 2. Numbers of participants divided over 
tertiles of WBC count and CRP levels.











nt 1st 97 48 45
2nd 65 60 55
3rd 54 43 94
Abbreviations: CRP: C-reactive protein; WBC : white 
blood cell count. Bold values indicate concordant 
WBC and CRP tertiles
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one standard deviation (SD) in CRP level we found a 1.22 (95% CI = 1.10-1.35) increased 
risk for all-cause mortality. Similar increased mortality risks were observed for non-
vascular mortality (HR (95%CI) = 1.27 (1.11-1.45)). There was a tendency for an increased 
vascular mortality risk (HR (95%CI) = 1.15 (0.98-1.35) (Figure 1c).
There was no significant interaction between WBC count, CRP levels and all-cause mor-
tality (p=0.56), and also not for vascular (p=0.86) and non-vascular mortality (p=0.48). 
Because there was no interaction between WBC count, CRP levels and all-cause and 
cause specific mortalities, we additionally adjusted the WBC associations with mortality 
for baseline levels of CRP (Figure 1). Adjustment for the level of CRP in the association 
between WBC count and all-cause mortality did also not materially change the results. 
The mortality risks for all-cause mortality (HR (95%CI) = 1.20 (1.09-1.33)) and for vascular 
mortality (HR (95%CI) = 1.32 (1.16-1.50)) remained significant after adjustment for CRP, 
whereas statistical significance was not reached for non-vascular mortality (HR (95%CI) 
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Figure 1: White blood cell (WBC) count, C-reactive protein (CRP) levels and mortality risk adjusted 
for sex, institutionalization and smoking status (never smoker, former smoker, current smoker). Data 




= 1.10 (0.94-1.28) (Figure 1b). Moreover, adjusting the association between CRP levels 
and mortality for baseline WBC count levels did not materially change the results (Figure 
1d). This indicates that both WBC count and CRP level are independent predictors of 
mortality at old age.
To exclude the possibility that this association was driven by pre-existing disease we 
repeated all analyses stratified for presence and absence of comorbidity at baseline. The 
mortality risks of participants without comorbidity were highly comparable with the 
mortality risks in the group with co-morbidity which were all significantly higher than 
unity with increasing WBC counts or increasing CRP levels (data not shown). Moreover, 
we adjusted all analyses for the number of co-morbidities. The results did not materially 
change after adjustment (data not shown). Furthermore, we additionally adjusted all 
analyses for known cardiovascular risk factors, such as triglycerides, high density lipo-
protein (HDL) and low density lipoprotein (LDL) levels, systolic and diastolic blood pres-
sure, and body mass index. Adjustment for these risk factors did not materially change 
our results (results not shown).
Discussion
We investigated the association between WBC count, CRP level and mortality in the old-
est old. We found that both WBC count and CRP levels were independent predictors of 
mortality, in a dose-response manner. Stratification for comorbidity did not affect this 
association.
Our results confirm previous findings in middle-aged study populations that high WBC 
count predicts mortality independent of smoking and other co-morbid risk factors (1-
4,6-10,12,13), and separately in a study of older men (age range 64-84 years) (5) and 
older women (age range 50-79 years). (15) As far we know it has not been described 
before that WBC count is also an indicator for mortality in the oldest old (above 85 years 
of age). It is unlikely that underlying diseases at baseline may have affected our observed 
associations because stratifying the analyses for comorbidity did not change our results.
In the twentieth century, WBC count was the most used marker for systemic inflamma-
tion. However, nowadays in clinical practice CRP levels are believed to be the most valu-
able diagnostic marker to predict mortality. (14-17) Several studies have shown that an 
increased CRP level in the elderly participants predicts an increased mortality risk, both 
vascular and non-vascular. (22-24) To our knowledge, the comparison of these both 
predictors, WBC count and CRP levels, in the relation with increased mortality has not 
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been described before. Here we show that both CRP and WBC count are independent 
predictors for mortality in the oldest old.
Although we found WBC predicting mortality, the pathophysiological explanation 
about the mechanism of elevated WBC count and mortality is not well understood. It 
is not known whether elevated WBC count is involved directly in the pathogenesis of 
vascular diseases or whether an increased WBC count is merely a risk indicator for other 
factors causing vascular damage. (25) For CRP this has been investigated by Mendelian 
randomization. (26-28) Participants carrying genetic variation within the CRP gene that 
determines a high CRP level did not have an increased risk for vascular mortality. (26-28) 
This indicates that high CRP plasma levels are not causally related to vascular disease 
but is merely an output of the vascular disease (reverse causality). Both WBC count and 
CRP levels are therefore risk indicators for an increased mortality risk.
Strength and limitations
The present study has several important strengths. First, these data are from a large, rep-
resentative cohort of the oldest old and so far we know the relationship between CRP, 
WBC count and mortality has not been described in such a large representative cohort 
of this age. Second, because almost all our participants had a WBC count within the 
clinically defined normal range a potential contribution from reduced immune function 
or chronic infectious diseases is unlikely to have played an important role in the findings.
Potential limitations of this study must be considered. We used a single CRP and WBC 
count measurement to predict mortality. Multiple measurements over time may provide 
more accurate information for predicting future disease and therefore mortality. If so, 
with one single CRP and WBC measurement in our study cohort at baseline we may 
have underestimated the effect on mortality at old age. Moreover, although the number 
of WBCs can vary from day to day within one participant (29), a single measurement 
has previous been shown to predict risk for morbidity and mortality. Furthermore, the 
hazard ratios with WBC operated seemingly different from those associated with CRP 
for vascular and nonvascular mortality. However, the confidence intervals around the 
estimates are relatively wide. This makes it difficult to interpret whether there is a true 
difference. Finally, differential cell counts were not performed in the Leiden 85-plus 
Study, so we could not provide information about what types of leucocytes were more 
prone to be elevated with increased mortality risk at old age.
Conclusion
Our results suggest that that levels of WBC and CRP both are independently associated 
with mortality in the oldest old. Additional studies are needed to determine whether 
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interventions to decrease these markers can reduce the increased mortality risk. In 
clinical practice, it is necessary to pay more attention to the potential of WBC count as a 
predictor for mortality in the oldest old.
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Introduction In older persons, anemia is associated with a number of unfavorable out-
comes. In approximately 30% of older persons with anemia, the cause of the anemia is 
unexplained. We assessed the clinical differences between subjects with explained and 
unexplained anemia and investigated whether these subjects have different mortality 
patterns compared to subjects without anemia.
Methods In the Leiden 85-plus Study, an observational population-based prospective 
follow-up study in Leiden, The Netherlands, blood samples were drawn from 491 per-
sons aged 86 years. The study population was divided in three groups: (1) no anemia 
(reference group, n=377), (2) explained anemia (iron deficiency, folate deficiency, 
vitamin B12 deficiency, signs of myelodysplastic syndrome, or renal failure, n=74), and 
(3) unexplained anemia, (n=40). Mortality risks were estimated with Cox-proportional 
hazard models.
Results Haemoglobin levels were significantly lower in subjects with explained anemia 
than in subjects with unexplained anemia (p<0.01). An increased risk for mortality was 
observed in subjects with explained anemia (HR 1.93, 95%CI 1.47-2.52), p<0.001), but 
not in subjects with unexplained anemia (HR 1.19, (95%CI 0.85-1.69), p=0.31). Adjusted 
analyses (sex, co-morbidity, MMSE, institutionalised and smoking) did not change the 
observed associations for both explained and unexplained anemic subjects.
Conclusion Older subjects with unexplained anemia had similar survival compared to 
non-anemic subjects. Increased mortality risks were observed in subjects with explained 
anemia compared to non-anemic subjects.
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Introduction
The incidence and prevalence of anemia increase with age. (1,2) In older subjects anemia 
is associated with unfavorable events including death (3-6), dementia (7), cardiovascular 
diseases (8), and functional dependence. (9,10) Clinical investigation into the cause of 
anemia in older patients is often complicated by the co-morbidity characterising this pa-
tient group. Especially cognitive disorders and physical disabilities hamper reliable his-
tory taking and physical examinations, the cornerstones of medical practice. Therefore 
in clinical practice, the initial laboratory results are indicative for making the decision for 
further and often more invasive investigations in these patients. Since any procedure 
may lead to a deterioration of the current condition of the older patient invasive investi-
gations should be limited to a minimum.
Chronic renal failure and iron-deficiency are the most common causes for anemia in 
older subjects (1,11,12), often caused by severe underlying diseases like atherosclerosis 
and gastro-intestinal malignancies, respectively. Other well known causes in clinical 
practice for anemia are folate- and vitamin B12 deficiency. The role of vitamin B12 defi-
ciency as predictor for the presence of anemia in this population, however, is still subject 
to discussion. (13,14) Another serious cause of anemia in the elderly is myelodysplastic 
syndrome (MDS), a heterogeneous disorder characterized by ineffective haematopoiesis 
resulting in low peripheral blood counts. (15,16)
Several epidemiological studies have found that up to 30% of anemia in the older popu-
lation is unexplained, even when extensive clinical information is available. (15,17,18) 
The clinical relevance of unexplained anemia is unclear. In the present study, we as-
sessed clinical differences between explained and unexplained anemia in older subjects 
and investigated how mortality risks differ by type of anemia.
Methods
Study population
All data were derived from the Leiden 85-plus Study, a prospective follow-up study of 
subjects aged 85 years at baseline. At baseline, all individuals were living in Leiden, The 
Netherlands. There were no exclusion criteria for study participation. All subjects were 
visited at their place of residence where interviews took place and venous blood samples 
were drawn. Between 1997 and 1999, the Leiden 85-plus Study enrolled 599 subjects at 
baseline. (19) For the present analysis, we included 491 subjects aged 86 years. Of the 
108 subjects that were not included in the present analysis, 47 died before the age of 
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86 years, 39 refused further participation, 16 refused blood sampling, and in 6 subjects 
no erythropoietin measurement was available due to technical problems. The Medical 
Ethical Committee of the Leiden University Medical Center (LUMC) approved the study 
and all participants provided informed consent for study participation.
Laboratory measurements
All blood samples were collected in sterile EDTA tubes. Measurements of haemoglobin, 
mean corpuscular volume (MCV) and erythrocyte count, white blood cell count and 
platelet count were done with a fully automated system (Sysmex XE-2100, TOA Medical 
Electronics, Kobe, Japan). Serum erythropoietin levels were measured using the enzyme 
immunoassay (EIA, Immulite 2500, Siemens Medical Diagnostics, Tarrytown, NY), which 
had a sensitivity of 1.2 mU/ml and a coefficient of variation less than 6%. Creatinine was 
measured according to the Jaffe method (Hitachi 747, Tokyo, Japan). Creatinine clear-
ance was estimated with the Modification of Diet in Renal Disease equation (MDRD). 
(20) C-reactive protein (CRP) measurement was done in one batch using the Dual Count 
Solid Phase No Boil Assay (Diagnostic Products Corp, Los Angeles, CA, USA). Ferritin, 
folate, vitamin B12 were determined in one batch using the Dual Count Solid Phase No 
Boil Assay (Diagnostic Products Corp, Los Angeles, CA, USA).
Mortality
All subjects were followed up for mortality until 1 February 2008. For the deceased 
participants, the cause of death was obtained from Statistics Netherlands. Only the pri-
mary cause of death on the death certificate was used in our analyses. The International 
Classification of Diseases (ICD) codes I00-I99 were used for cardiovascular mortality. For 
non-vascular mortality, all ICD codes except I00-I99 were used.
Study groups
For the present study, the study population was divided in three groups: a group with no 
anemia (reference group), a group with a known cause for anemia (explained anemia) 
and a group with an unknown cause for anemia (unexplained anemia). Explained and 
unexplained anemia are two different identities; explained anemia, often due to chronic 
diseases or malignancies, is characterized by significant higher CRP, Interleukin-6 levels 
or higher erythropoietin levels. In persons with unexplained anemia, lower CRP, lower 
lymphocyte counts and EPO levels are found, assuming a totally different pathophysi-
ological form of anemia.Anemia was defined according to the criteria of the World 
Health Organization (21) as haemoglobin levels lower than 12.0 g/dl (7.5 mmol/l) for 
women and 13.0 g/dl (8.1 mmol/l for men. Explained anemia was defined as anemia 
in the presence of iron deficiency (ferritin <20 ng/mL), renal failure (MDRD < 50 ml/
min/m2), vitamin B12 deficiency (<150 pmol/mL), folate deficiency (<7.0 nmol/mL), or 
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signs of myelodysplastic syndrome. Myelodysplastic syndrome was defined as anemia 
together with leucopenia (white blood cell count less than 3.5 x 109), or thrombopenia 
(platelet count less than 150 x 109). Unexplained anemia was defined as the presence of 
anemia with normal ferritin, vitamin B12, folate and creatinine concentrations.
Additional study parameters
Information on the presence of chronic disease (diabetes mellitus, chronic obstructive 
pulmonary disease (COPD), arthritis, myocardial infarction, heart failure, stroke and 
malignancy) was obtained from general practitioners, nursing home physicians and 
pharmacy records. (22) Cognitive function was measured with the Mini-Mental State 
Examination (MMSE). (23) All participants were interviewed about current and former 
smoking habits.
Statistical analyses
Data are presented as number (percentages) for dichotomous parameters and as me-
dian (interquartile range) for continuous parameters. Differences in laboratory values 
between anemic (both explained and unexplained) and non-anemic subjects (the refer-
ence group) were determined by Mann-Whitney U test. Mortality differences between 
anemic and non-anemic subjects were assessed with Cox regression analysis, adjusted 
for gender, co-morbidity, MMSE, institutionalisation, smoking and haemoglobin level. 
Mortality was visually depicted with Kaplan-Meier survival curves. Mortality differences 
between subjects with explained and unexplained anemia was additionally adjusted for 
haemoglobin level.
Since previous results from the Leiden 85-plus Study showed no association between 
vitamin B12 deficiency and anemia (13), we repeated all analyses excluding vitamin B12 
deficiency from the explained anemic group.
The SPSS software (version 16.0.1, SPSS Inc, Chicago, Ill) was used for all statistical analy-
ses. P-values lower than 0.05 were considered statistically significant.
Results
Baseline characteristics
Baseline characteristics of the 491 subjects are presented in table 1. A total of 108 (22%) 
subjects were institutionalised in a nursing home or care home for older persons, 315 
(64%) had one or more chronic diseases, 49 (10%) had a history of myocardial infarction, 
and 58 (12%) a history of stroke. A total of 131 subjects (27%) had renal insufficiency 
with an estimated glomerular filtration rate < 50 ml/min/1.73m2 (MDRD). Of the 114 
(23%) cases of anemia, 74 (65%) were explained and 40 (35%) were unexplained. Of the 
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74 subjects with explained anemia, 13 (19%) had iron deficiency, 42 (56%) had renal fail-
ure, 4 (5%) folate deficiency, 11 (15%) vitamin B12 deficiency and 4 (5%) myelodysplastic 
syndrome.
Anemia
Table 2 shows the hematological characteristics of the subjects with explained anemia, 
unexplained anemia and their counterparts without anemia. Hemoglobin levels were 
Table 1. Baseline characteristics of the subjects at age 86.
n=491
Women (%) 331 (67)
Institutionalized (%) 108 (22)
MMSE-score (median, IQR) 26 (22-28)
Current and/or past smoking (%) 231 (47)
Chronic diseases (%) 315 (64)
 Malignancies (%) 92 (19)
 Diabetes Mellitus (%) 73 (15)
 COPD (%) 49 (10)
 Arthritis * (%) 162 (33)
 Renal insufficiency † (%) 131 (27)
 Myocardial infarction (%) 49 (10)
 Stroke (%) 58 (12)
Anemia (%) 114 (23)
 Explained anemia (%) 74 (15)
  Iron deficiency‡ (%) 13 (19)
  Renal anemia ∫ (%) 42 (57)
  Vitamin B12 deficiency ¶ (%) 11 (15)
  Folate deficiency # (%) 4 (5)
  Myelodysplastic syndrome**(%) 4 (5)
 Unexplained anemia (%) 40 (8)
Follow-up time (years) 6 (3-9)
Continuous parameters are presented as median (interquartile range).
Categorial data are presented as numbers (percentages).
*Arthritis was defined as polymyalgia rheumatica, rheumatoid arthritis and osteoarthrosis.
†Renal insufficiency was defined as creatinine clearance <50 ml/min/1.73m2 calculated by Modification of Diet in 
Renal Disease formula.
‡ iron deficiency was defined as ferritin <20 ng/mL; ∫ renal anemia was defined as having anemia and creatinine 
clearance <50 ml/min/1.73m2; ¶ vitamin B12 deficiency was defined as <150 pmol/mL; # folate deficiency was 
defined as <7,0 nmol/mL; ** myelodysplastic syndrome vitamin was defined as anemia together with leucopenia 
(white blood cell count less than 3.5 x 109), and thrombopenia (platelet count less than 150 x 109)
Abbreviations: MMSE, Mini Mental State Examination; COPD, Chronic Obstructive Pulmonary Disease
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significantly lower in the subjects with explained anemia than in the subjects with un-
explained anemia (p<0.01) As expected, median erythropoietin levels were significantly 
higher in the subjects with anemia than in the subjects without anemia (9.6 mIU/ml) 
(p<0.01). However, median erythropoietin levels were similar in subjects with explained 
anemia and those with unexplained anemia, (11.5 mIU/ml vs 12.1 mIU/ml, p=0.88). 
Only in the group with explained anemia, CRP was significantly higher than in those 
without anemia (p<0.05). No differences in comorbid illnesses (malignancies, diabetes 
mellitus, COPD, arthritis, myocardial infarction and stroke), smoking, MMSE and institu-
tionalisation were found between the explained and unexplained anemic groups (data 
not shown).
Mortality risks
Survival differences between subjects with explained anemia, unexplained anemia and 
without anemia from age 86 onwards are visually depicted in Figure 1. An increased 
risk for all-cause mortality was found in the group of subjects with explained anemia 
(HR 1.93, 95%CI 1.47-2.52), p<0.001) compared with the group of subjects without 
anemia. Subjects with unexplained anemia had no increased risk for all-cause mortality 
compared with non-anemic subjects (HR 1.19, (95%CI 0.85-1.69), p=0.31). Adjustment 







Hemoglobin (g/dL) 11.4 (10.4-11.8)** 11.7 (11.2-12.2)** 13.4 (12.8-14.1)
Hematocrit (%) 0.35 (0.32-0.36)** 0.36 (0.34-0.37)** 0.41 (0.38-0.43)
MCV (fL) 90 (86-93)** 91 (88-94) 91 (89-94)
Erythrocytes (x 109/L) 3.9 (3.6-4.1)** 3.9 (3.7-4.1)** 4.5 (4.3-4.7)
Leucocytes (x 109/L) 6.5 (5.1-7.6) 6.0 (5.0-7.1) 6.3 (5.3-7.5)
Platelets (x 109/L) 225 (172-272) 235 (194-282) 227 (191-267)
Erythropoietin (mIU/ml) 11.5 (8.8-17.2)** 12.1 (9.7-15.0)** 9.6 (7.5-12.8)
Creatinine (µmol/L) 105 (88-135)** 93 (79-100) 91 (80-106)
MDRD (ml/min/1.73m2) 48 (37-66)** 62 (54-68) 58 (50-68)
Albumin (g/L) 39 (36-41)** 39 (36-41)** 41 (39-43)
CRP (mg/L) 6.0 (2.0-12.0)** 4.0 (1.0-8.0) 3.0 (0.0-7.0)
Ferritin (mg/L) 103 (37-229)* 93 (49-190) 118 (64-202)
Vitamin B12 (pmol/L) 282 (190-339) 302 (209-451) 256 (204-338)
Folic acid (nmol/L) 11 (9-14)** 13 (11-17) 13 (10-16)
Data are presented in median (interquartile range). P-value calculated by Mann-Whitney U test.
*=P<0.05, ** P≤ 0.01 compared to subjects without anemia.
Abbreviations: MCV; Mean Corpuscular Volume, CRP; C-reactive Protein.
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for sex, co-morbidity, MMSE, institutionalization and smoking did not change these 
associations for subjects with explained anemia ((HR 1.93 (95%CI 1.23-3.02), p =0.004) 
and for subjects with unexplained anemia ((HR 1.19, (95%CI 0.79-1.79), p=0.39). When 
we repeated all analyses excluding vitamin B12 deficiency from the explained anemic 
group, the results were not materially different.
Subjects with explained anemia had an increased mortality risk compared to subjects 
with unexplained anemia (HR 1.61 (95%CI 1.09-2.21), p=0.04). Adjustment for sex, co-
morbidity, MMSE, institutionalisation, smoking and hemoglobin did not change this 
association. In this analysis, sex (HR 2.15 (95%CI 1.59-2.90), p<0.0001), hemoglobin 
level (HR 1.41 (95%CI 1.16-1.73), p=0.001), CRP (HR 1.02 (95%CI 1.00-1.02), p= 0.001) 
and MMSE (HR 1.07(95%CI 1.04-1.09), p=0.0001) were independently associated with 
mortality risk.
Furthermore, the all-cause, cardiovascular and non-cardiovascular mortality risks for 
participants with explained and unexplained anemia were studied. No statistically sig-
nificant differences were found in cardiovascular mortality risk between the explained 
and unexplained anemic group (HR 1.83 (95%CI 0.90-3.74), p=0.09). However, no differ-
ence was found in non-cardiovascular mortality risk between these two groups (HR 1.36 
(95%CI 0.81-2.32), p=0.24) (data not shown).
 
Figure 1. Survival of subjects with no anemia (n=377), explained anemia (n=74), and unexplained anemia 
(n=40) from age 86.
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Discussion
The main finding of this study is that older subjects with explained anemia had an 
almost two-fold increased mortality risk compared to subjects without anemia, whereas 
in subjects with unexplained anemia no excess mortality was found. These findings pos-
sibly suggest that in older persons anemia is only relevant for survival when a clinical 
explanation for the cause of anemia can be demonstrated.
In our study sample, we found that in 37% of anemic subjects no clinical explanation 
for anemia could be found similar to earlier reports. Data from a non-institutionalised 
US population assessed in the third National Health and Nutrition Examination Survey 
(1988-1994) showed that unexplained anemia was present in one third of the older 
adults (>65 years) with anemia. (1) Another study reported that no evident cause for 
anemia in a representative sample of older Europeans (>65 years) was found in 36.8 % of 
the anemic participants. (18) Moreover, in a study conducted among subjects of a nurs-
ing facility almost one-third of the anemic subjects qualified as clinically unexplained. 
(17) Hence, our findings on the prevalence of explained and unexplained anemia in 
elderly subjects corresponds well with the prevalences reported in the literature.
We found a twofold increased mortality risk in older persons with explained anemia com-
pared with the non-anemic subjects. We regarded subjects as having explained anemia 
when they met obvious clinical criteria as causes for anemia, i.e. iron-, folate-, vitamin B12 
deficiency, renal failure, and myelodysplastic syndrome. Because of the design of our study, 
we were not informed about the specific underlying diseases causing these types of anemia. 
The reason for the observed difference in mortality between the subjects with explained 
anemia and unexplained anemia or without anemia is not obvious from our study. Between 
the three groups no differences in cause of death were found. It is tempting to speculate 
that persons with iron deficiency would have an increased mortality risk because of the 
presence of intestinal malignancy and that persons with a renal anemia would preferably 
die because of cardiovascular disease. However further analysis of our data failed to dem-
onstrate such relationships, probably because of the small number of subjects.
Higher serum CRP levels were found in the group of subjects with explained anemia 
when compared to subjects with unexplained anemia and subjects without anemia. It 
may therefore be suggested that the underlying cause of the anemia is associated with 
a chronic inflammatory response which may contribute to the observed increased mor-
tality. Since there was significant predominance of renal insufficiency and myocardial 
infarction in the explained group the observed elevated CRP may be the result of the 
inflammatory status due to underlying atherosclerotic disease.
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In contrast to the group of subjects with known causes for anemia, the group with unex-
plained anemia had no increased mortality risk. To our knowledge, this is a new finding 
with potentially important clinical implications. It possibly suggests that when in older 
persons no cause for an anemia can be demonstrated by laboratory measurements, no 
further clinical investigations might be necessary. Anemia in general is associated with 
an increased mortality risk, also in the oldest old. (4-6) An explanation for the present 
observation is still subject to speculation. It can be hypothesized that in subjects with 
unexplained anemia, a relatively low hemoglobin level is part of their “normal” phe-
notype. However, the fact that erythropoietin levels in the subjects with unexplained 
anemia were similar to the level in the group with explained anemia, might suggest a 
physiological response to a relatively low hemoglobin level in these subjects. Based on 
the selection criteria used for this group, the absence of increased co-morbidity and the 
relatively normal CRP levels, it could be suggested that anemia in this group might be 
caused by impaired erythrocyte production due to an age-associated diminished hema-
topoietic stem cell proliferative capacity or, as suggested earlier, or by an one lineage 
MDS presenting as anemia without white blood cell or platelet features with a very low 
risk of further deterioration. (15) However, new studies are required to shed light on this 
clinically important finding.
Strengths and limitations
Our study contributes to the extensive discussion about the relationship between age-
ing and anemia. A strong point of our study is its prospective follow-up setting, permit-
ting us to analyse survival of the oldest old subjects aged 86 years. A limitation of the 
study is the relatively limited sample size of subjects with explained and unexplained 
anemia. However, as mentioned, the prevalence of the subjects with unexplained 
anemia is remarkably similar to those reported in other studies. (1,17) Therefore we 
believe that our findings may have a high external validity. Another limitation is that we 
were only able to draw conclusions of subjects of 86 years or older who were still alive, 
more research have to be done on the impact of unexplained anemia and mortality of 
subjects younger than 86 years.
Conclusion
The present findings show that in contrast to older subjects with explained cause for 
anemia, older subjects with unexplained anemia based on initial laboratory measure-
ments have no increased mortality risk compared to subjects without anemia, suggest-
ing that further clinical and often invasive evaluation to the cause of anemia is possibly 
not necessary in this very old group of patients. This observation should be confirmed in 
other prospective observational studies and in dedicated intervention studies.
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Haemoglobin levels predicts length of hospital 
stay after hip fracture surgery in older patients





Introduction Treating anaemia in older patients who have undergone hip fracture 
surgery is to enhance functional recovery. The relationship between peri-operative hae-
moglobin levels and outcome after hip fracture surgery are controversial. We assessed 
whether higher haemoglobin levels predict length of hospital stay after hip fracture 
surgery in elderly subjects.
Methods A follow-up study in a historical cohort was performed in 317 patients aged 
65 years old undergoing hip fracture surgery over the period 2004-2006 at the Leiden 
University Medical Centre. Linear regression analysis was used to assess the association 
between pre- and post-operative haemoglobin level and length of hospital stay after 
controlling for age and sex.
Results Anaemia after hip fracture surgery was present among 86% of the patients. 
Length of hospital stay after hip fracture surgery in elderly subjects with post-operative 
anaemia (10.7 days) was significant longer than in elderly subjects without post-
operative anaemia (7.5 days, p =0.007). Post-operative haemoglobin levels and length 
of hospital stay were inversely related (p=0.013). The length of hospital stay was not 
related with pre-operative haemoglobin level.
Conclusion Higher postoperative haemoglobin levels predicts shorter length of hospi-
tal stay after hip fracture surgery in the elderly. A definitive randomized clinical trial has 
to demonstrate whether this association is causal.
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Introduction
Hip fracture is a main cause of disability and death in older people, and numbers are 
expected to increase sharply in the near future. (1, 2) Poor functional recovery after 
hip surgery is related to loss of independence and long-term mortality. (3) Because hip 
fracture surgery is associated with considerable blood loss, some have reported that low 
peri-operative haemoglobin levels in older patients are associated with increased mor-
bidity and mortality after hip surgery. (4-6) Functional recovery can be facilitated when 
treating anaemia. Moreover, Foss et al concluded that anaemia after hip fracture surgery 
in older patients impedes functional mobility in the early post-operative phase. (7)
Nowadays most hospitals in the Netherlands have a restricted transfusion policy after 
surgery due to associated risks with allogenic red blood cell transfusions, like infectious 
complications or acute lung injury. (8-11) A guideline that is frequently used in the Neth-
erlands, advises red blood cell transfusion for patients over 60 years, if the haemoglobin 
level drops below 8g/dL or if anaemia is symptomatic. (12) This guideline is based on 
outcomes of studies that included patients younger than 60 years. (13) The haemoglobin 
threshold at which postoperative red-cell transfusion is warranted is controversial (14) and 
data of the benefits of red-cell transfusion after hip surgery in older subjects are scarce.
We assessed in older patients whether peri-operative higher haemoglobin level in-
creases functional recovery and therefore shortens the length of hospital stay after hip 
fracture surgery. Therefore we performed a follow-up study in a historical cohort of older 
patients with hip surgery to determine whether pre- and post-operative haemoglobin 
levels predict length of hospital stay, which may provide provisionally evidence that a 
restricted transfusion policy has a (physical) cost.
Methods
Study population
Patients 65 years of age or older who were undergoing primary surgical repair of a hip 
fracture between 2004-2006 at the Leiden University Medical Centre by either trauma 
surgeons or orthopaedic surgeons were reviewed (n= 344). Patients with a re-operation 
within 1 month because of complications were excluded (n= 27). The total cohort in-
cluded 317 subjects aged 65 years and over.
Peri-operative haemoglobin levels and length of hospital stay were retrieved from the 
hospital’s patient information system. Length of hospital stay, the outcome measure for 
functional recovery, was defined as the difference between the day of admission and 
the day of discharge. The pre- and postoperative haemoglobin measurements reflected 
daily practice. The pre-operative haemoglobin value was measured. Furthermore, for 
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the postoperative haemoglobin level, the value measured one the day after surgery 
was used. If this was not available, the postoperative haemoglobin level measured in 
the recovery room was used. Anaemia was defined by the criteria of the World Health 
Organization.(15) The reference interval for haemoglobin concentration was set at 12-16 
g/dL for women and at 13-18 g/dL for men. Anaemia was defined as a haemoglobin level 
of ≤ 12 g/dL for women and ≤ 13 g/dL for men. No in- or exclusion criteria were used, 
except an age of 65 years and over.
There was no permission required of the Leiden Medical Ethical Committee, because 
the research was done with historical data of patients receiving usual clinical care. No 
additional blood samples or questionnaires were needed.
Statistical analysis
The statistical analysis proceeded in various stages. First, descriptive statistics were per-
formed using means and standard deviations (SDs) for continuous variables. Then, mul-
tivariate regression analysis was used to assess the association between pre- and post-
operative haemoglobin level and length of hospital stay. Because length of hospital stay 
was not normally distributed, data were log transformed. Pre- and post-operative levels 
of haemoglobin were simultaneously entered in a linear regression model adjusted for 
age and sex. Then, results were transformed back to the original scale. All results on the 
association between haemoglobin and length of hospital stay are therefore presented 
as geometric means and corresponding 95% confidence intervals. All analyses were 
performed with SPSS for Windows (version 16.0, SPSS Inc, Chicago,Ill).
Results
The study population comprised of 223 women and 94 men, undergoing hip fracture 
surgery with a mean age of 80.4 years (range, 65-104). The clinical characteristics of the 
patients are shown in Table 1. 
Table 1. Clinical characteristics of the study patients.
All subjects
Age, years (range) 80.4 (65-104)
Male/female 94/223
Peri-operative transfusion, n (%) 136 (43)
Pre-operative haemoglobin (g/dL) 12.4 (1.7)
Pre-operative anaemia, n (%) 107 (33)
Pathologic/traumatic fracture 12/305
Data are presented as mean (SD), unless otherwise stated.
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The mean (SD) haemoglobin concentration before hip surgery was 12.6 (1.7) g/dL. After 
hip surgery the mean (SD) haemoglobin level was 10.4 (1.7) g/dL, the mean difference 
being 2.4 (1.4) g/dL. Before hip fracture repair anaemia was present in 33 % of the older 
patients. After surgery it was present in 86 %. At hospital discharge anaemia was still 
present in 68%. In-hospital mortality was less than 4 % (12/317 patients).
The mean length of hospital stay after hip fracture surgery in subjects with and without 
pre-operative anaemia was similar (9.6 vs 9.9 days, p=0.741) (Figure 1). In subjects with 
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Figure 1. Pre- and post-operative anaemia of hip fracture surgery elderly patients in relation to length of 















































Figure 2. Categories of pre- and post-operative haemoglobin levels for hip fracture surgery in elderly 
subjects in relation to length of hospital stay, adjusted for age and sex.
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without post-operative anaemia it was 7.5 days (p=0.007) (Figure 1). When pre- and 
post-operative haemoglobin levels were simultaneously entered into a linear regres-
sion model, adjusted for age and sex, pre-operative haemoglobin was not associated 
with length of hospital stay (p=0.130), while post-operative haemoglobin level was in-
versely correlated with a significant shorter hospital stay (p=0.013) (Figure 2). Moreover, 
subjects with no post-operative decrease in haemoglobin levels had a mean hospital 
stay of 9.2 days compared to 10.3 days for subjects with more than 3 g/dL decrease in 
haemoglobin (p=0.03).
Discussion
In this study we find that after hip fracture surgery, older patients with post-operative 
anaemia were significantly longer admitted postoperatively compared to those without 
anaemia after hip fracture repair.
The significant blood loss after hip fracture surgery in our study is in accordance with the 
literature. (16) This acute onset of post-operative anaemia in a large proportion of the 
patients has important clinical impact in older patients, not only on the cardiovascular 
system but also on the functional status of individuals, frequent in-hospital events, 
costs, resource utilization and even mortality. (4,6,17-19) Nevertheless, only few stud-
ies have evaluated the impact of acute anaemia on these outcomes in older subjects. 
(6,7,14,20) Since acute anaemia can cause such a wide spectrum of complications here 
we have chosen the length of hospital admittance as global outcome measure of this 
study, because it integrates all the relevant clinical events having an adverse effect on 
the functional recovery of the patient in a clinical setting.
The fact that older patients with post-operative anaemia stayed significantly longer in 
the hospital than patients without anaemia, may suggest that acute anaemia due to 
the blood loss has negative clinical impact on the post-operative functional recovery 
of these patients. The fact that 80% of all patients were anaemic after the surgical pro-
cedure results from the stringent blood management guidelines. (12) With incidence 
rates of less than 0.1 % for acute lung injury and of less than 0.01% for viral and bacterial 
infections due to red blood cell transfusions, the clinically important risks associated 
with these transfusions is low, and even lower when using leucocyte depleted red blood 
cell transfusions. (11,21,23) In contrast to the post-operative haemoglobin level, pre-
operative haemoglobin was not associated with the length of hospital stay after hip 
fracture surgery.
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Strength and limitations
This study has several limitations. First, we used a historical data collection, which did 
not permit measurement of haemoglobin levels at standardized time periods. Second, 
we could not control for differences in patient characteristics for example like co-morbid 
illnesses and institutionalization, which both influence hospital stay duration. However, 
the fact that we found no significant relation between pre-operative haemoglobin lev-
els and hospital stay virtually rules out that pre-existing co-morbidity has influenced 
our results. Third, because of the permanent shortage of post-operative rehabilitation 
places outside the hospital after any type of surgery in our country, patients may have 
stayed longer in hospital than strict medical necessary, but this is likely to be randomly 
distributed over the study groups. Fourth, information about the timing of the given 
erythrocyte transfusions is lacking.Therefore we were not able to include the influence 
of transfusions on the length of hospital stay in our analysis. Furthermore, in our study 
population none of the patients received intravenous iron administration nor erythro-
poietin supplements.
Conclusion
In conclusion, this analysis generates the hypothesis that high post-operative hae-
moglobin values after hip fracture surgery in older patients is associated with shorter 
length of hospital stay. Length of hospital stay seems not related to pre-operative 
haemoglobin level. Our hypothesis requires testing in a randomized clinical trial. If a 
definitive prospective clinical trial demonstrates the same results and causality between 
higher post-operative haemoglobin levels and post-operative function and length of 
hospital stay after hip fracture surgery in older persons, current transfusion guidelines 
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The aim of the research presented in this thesis was to study the physiology and clinical 
impact of changes in the triad renal function, erythropoietin production and hemoglo-
bin levels in old age. The first part of this thesis focussed on the physiological aspects 
of age related decline in renal function and the relation with erythropoietin production 
and the maintenance of haemoglobin levels at old age. The second part of the thesis 
focussed on the consequences of changes in EPO, hemoglobin and other haematologi-
cal parameters as predictors or indicators for mortality in older subjects. The underlying 
motivation for this research was to gain more insight in the possible consequences of 
physiological changes of kidney and bone marrow function during ageing with the ob-
jective to support the development of an evidence-based approach in clinical practice 
for these very old people.
Physiology of haemoglobin, erythropoietin and the kidney
Physiology refers to the normal function of organs, whereas “insufficiency” or “ failure” 
is a pathological status. The knowledge of physiological processes taking place during 
ageing is of great importance because of the growing amount of the oldest old patients 
in daily practice. By 2050, oldest old people will account for one-fifth of all older per-
sons globally. (1) In general, human organs are not affected uniformly by ageing. The 
hematopoietic system does not show any marked decline during ageing. (2) Anemia, 
low haemoglobin level, is therefore not a normal finding at old age. (3,4) But when pres-
ent, with suggested prevalences of 40% in octarenarians (5), is associated with declined 
physical fitness, cardiovascular diseases and cognitive impairment. (6-9)
In contrast, renal function declines linearly with ageing. Chronic renal failure is predomi-
nantly a disorder of older people and predicts increased risk of all-cause and cardiovas-
cular mortality. (10,11) However, within the kidney, the production of erythropoietin, 
the principal regulator of red blood cell production, seems not to be impaired by ageing. 
Furthermore, it is suggested that erythropoietin has independent of renal function a 
predictive value on survival. (12)
All these associations with mortality and the different organ changes at old age can 
only be understood when unravelling the physiological processes caused by ageing. 
Moreover, knowledge about physiology and survival could benefit patients well being 




Implications of age on estimating renal function
Since it is virtually unfeasible to measure GFR, for example by measuring inuline clear-
ance in very old people, it is of great importance to calculate the most relevant estimate 
of GFR especially in the oldest old. The aim of the study described in chapter 2 was 
to study the effect of age on the –in clinical practice most used- formulae to compute 
renal function. The findings showed that the Cockroft-Gault formula, with inclusion of 
total body weight in the equation, is underestimating renal function at very old age 
in comparison with both MDRD and CKD-EPI formulae. Moreover, our study suggests 
that implementation of the newer CKD-EPI formula would raise the number of older 
individuals with chronic kidney disease. Based on these results it was concluded that 
estimation of renal function in very old persons can be facilitated by GFR equations, as 
long as clinicians realize that the precision of the formulae, C-G, MDRD and CKD-EPI, all 
have its own limitations.
The importance of adequate calculating renal function was further emphasized by the 
finding that in the oldest old subjects, impaired renal function (< 30ml/min/1.73m2) is 
associated with an increased mortality risk. We found the MDRD equation is the most 
discriminative equation in predicting mortality in comparison with C-G and CKD-EPI in 
this age category. However, population based studies with 24-hour urine collections or 
with inulin or iothalamate infusions for the measurement of creatinine clearance are for 
practical reasons undoable in large numbers of very old subjects. Therefore, without a 
golden standard there will be always an uncertainty in the exploration of the most rel-
evant equation(s) for calculating renal function in this age category. On the other hand, 
to find the most adequate calculated renal function for older people has important con-
sequences such as in therapeutic decision making procedures, referrals to nephrologists 
and as predictor for survival.
Haemoglobin, EPO and renal function throughout life
In chapter 3 the results of the study of the association between increasing age and serum 
levels of erythropoietin, haemoglobin and renal function in healthy individuals aged 
30-100 years are presented. The findings of this study, performed in the Bronovo Study, 
suggest that erythrocyte count and haemoglobin level remain stable throughout life, 
whereas a decrease of the reticulocyte count was observed with increasing age. Another 
important finding of our study was that we observed an increased erythropoietin level 




Two possible hypotheses explaining these findings are described. In short, the most 
likely hypothesis is that EPO levels rise as a result of an EPO resistance bone marrow 
as a consequence of ageing. This higher EPO level protects newly formed erythrocytes 
from destruction and prolongs the erythrocyte survival time resulting in a stable total 
erythrocyte count. While with increasing age, haematopoietic stem cell become less 
responsive to EPO resulting in a decrease in reticulocyte count. The second hypothesis 
is that primarily EPO increases as a response to local hypoxemia due to age-related local 
atherosclerosis within the kidney. Because of the EPO-induced prolongation of the red 
blood cell survival, erythropoiesis must be down-regulated in order to maintain a stable 
erythrocyte count. 
Nevertheless, the age related decline in renal function has no important consequences 
for the erythrocyte count and haemoglobin level throughout life, irrespective of the 
underlying homeostatic mechanism. Translating this interesting finding to clinical prac-
tice, is it important to realize that low erythrocyte count or low haemoglobin levels are 
not physiological, even in very old patients. The mechanism underlying the observed 
increasing EPO levels during ageing, suggesting progressive EPO resistance of the he-
matopoietic stem, should be subject to further investigation.
Haematological parameters in the oldest old
The study to access whether familial longevity can be attributed to sustained haema-
topoietic capacity compared to community dwelling older individuals is described in 
chapter 4. This study showed that familial longevity was associated with a benefit in sur-
vival, but no differences in haemoglobin level, leucocyte and thrombocyte count were 
found in comparison with subjects without familial longevity. Based on these results it 
was concluded that hematopoietic capacity cannot explain the survival benefit of those 
nonagenarians with familial longevity. Furthermore, it was found that all long living 
men and women with anemia had higher mortality rates than those without anemia. 
Therefore, lower haemoglobin levels in elderly subjects cannot be considered simply as 
a “result of ageing” but are in medical practice a reason for further clinical investigation 
with regard to the survival disadvantage.
Moreover, no relationship was found with low leucocyte or thrombocyte counts and 
mortality in subjects with familial longevity. The reported heritability estimates for 
hemoglobin, leucocytes and thrombocytes of respectively 0.37, 0.62 and 0.57 also 
indicate that hemoglobin levels are more volatile and therefore anemia reflects underly-
ing morbidity more than leucopenia and thrombopenia. However, longitudinal studies 
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including bone marrow biopsy have to be performed to study the bone marrow reserve 
capacity of long-living subjects.
Independent predictors for mortality
In chapter 5 we have investigated the relation of white blood cell count (WBC) and also 
C-reactive protein (CRP) with mortality in the oldest old in more detail.
Elevated levels of WBC count and CRP are associated with increased risk for morbidity 
and mortality in middle-aged populations.(13-15) However, we show, within the Leiden 
85-Plus Study, that both CRP and WBC count are also independent predictors for mortal-
ity in the oldest old in a dose-response manner. It is unlikely that underlying diseases 
at baseline have affected our observed associations because stratifying the analyses for 
comorbidity did not change our results. 
Although we found WBC to predict non-vascular and vascular mortality in the oldest 
old, the pathophysiological explanation on the mechanism between elevated WBC 
count and mortality is not well understood. For example, for vascular mortality, it is not 
known whether elevated WBC count is involved directly in the pathogenesis of vascular 
diseases or whether an increased WBC count is merely a risk indicator for other factors 
causing vascular damage.16 Our results suggest that increasing levels of WBC and CRP 
both are independently associated with increasing risk of mortality in the oldest old. 
Additional studies are needed to determine whether interventions to decrease these 
markers of inflammation can reduce the increased mortality risk. In clinical practice, it 
is necessary to pay more attention, besides CRP levels, to the potential of WBC count as 
a predictor for mortality in the oldest old, next to their potential to be a good predictor 
for infection.
Unexplained anemia: implications for survival?
In chapter 6 the association between unexplained anemia and survival is presented. Results 
showed that in our oldest old population 37% of the anemic subjects had anemia without 
an obvious clinical explanation. This relatively high prevalence of unexplained anemia in 
older subjects, means that for a substantial part of the elderly population no explanation 
will be found for their anemic status. Furthermore, it was shown that the older subjects 
with unexplained anemia had similar survival compared with subjects without anemia.
In contrast to the patients with unexplained anemia, an almost twofold increased mortal-




since unexplained anemia is a “diagnosis by exclusion”, consensus must be reached in 
the exclusion criteria necessary to arrive at a diagnosis of unexplained anemia. In our 
study we regarded older subjects as having unexplained anemia when they did not met 
obvious clinical criteria as causes for anemia, i.e. iron-, folate-, vitamin B12 deficiency, 
renal failure, and myelodysplastic syndrome.
These results suggest that when in older persons no cause for anemia can be demon-
strated, further clinical investigations is not necessary and allows for a watchful ‘wait and 
see’ strategy of these very old patients. Ideally this observation should be confirmed in 
prospective observational studies in older populations.
Haemoglobin level predicts length of hospital stay
Low haemoglobin levels and hip fracture are prevalent health conditions in elderly and 
often co-occur in elderly persons. The relationship between peri-operative haemoglobin 
levels and outcome after hip fracture surgery are controversial. The predictive value of 
haemoglobin level was studied in a historical cohort of older subjects with hip surgery 
in the Leiden Hipfracture Study and described in chapter 7. Post-operative haemoglobin 
levels and length of hospital stay were inversely related. Post-operative anemic subjects 
stayed significant longer in hospital after surgery. The length of stay was not related 
with the haemoglobin level before hip surgery. These results may suggest that in elderly 
patients acute onset anemia due to blood loss has negative clinical impact on the post-
operative functional recovery of these patients. It seems that these data are a sufficient 
reason for a prospective clinical trial to demonstrate that post-operative anemia have 
negative impact on length of hospital stay and on functional mobility in the early post-
operative phase. If that study shows the same results, than current transfusion guidelines 
in the Netherlands would have to be updated.
Nowadays most hospitals in the Netherlands have a restricted transfusion policy after 
surgery. The most used guideline advises red blood cell transfusion for patients over 60 
years, if the hemoglobin level drops below 5 mmol/L or if anaemia is symptomatic. This 
guideline is based on outcomes of studies that included only patients younger than 60 
years. Based on the present findings new prospective studies to investigate the benefits 
of red blood cell transfusion after (hip) surgery in older subjects are urgently needed.
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Conclusion and future perspectives
Knowledge of physiological changes in renal function, EPO and haemoglobin level 
and their impact at old age are essential for clinicians especially those working with 
older patients. The results of the studies presented in this thesis provide more insight 
in the physiological aspects of age related decline in renal function and the relation 
with erythropoietin production and the maintenance of haemoglobin levels at old age. 
Furthermore, these results allow us to speculate about the predictive value of renal func-
tion, EPO and haemoglobin as markers of mortality in a clinical population of oldest old 
patients. Proper knowledge of these markers could contribute to increased attention 
of clinicians for the increased mortality risk of their oldest old patients. Furthermore, 
knowledge of these markers could be helpful in tailor made medicine, individual prog-
nostication and decision making procedures, in the oldest old patients.
Three phenomena in oldest old subjects needs special attention for further study; the 
most adequate renal function equation, the value of EPO and the role of unexplained 
anemia.
Moreover, the challenge for calculating renal function at old age, is to understand the 
imperfections of the different renal function equations. It is of interest that in the oldest 
old the MDRD formula might be the best estimate and the newer CKD-EPI formula would 
raise the number of older individuals with chronic kidney disease in comparison with 
the MDRD formula, with consequences for therapeutic decision making procedures and 
resulting in more hospitalizations. Furthermore, referrals to nephrologists of increasing 
numbers of these oldest old patients could raise other dilemmas. The benefit of kidney 
biopsy or renal replacement therapy of those older people with their comorbidities 
must weighted against the complications and must add quality of life.
EPO levels in older subjects were found relatively low only when severe renal failure 
(< 30ml/min/1.73m2) was present. Further research need to be done to confirm these 
results in other populations of elderly people. If so, older subjects with severe renal 
dysfunction may be considered for erythropoietin substation therapy, which has been 
shown to improve quality of life in (pre)dialysis and cancer patients.
With regard to the best diagnostic approach in oldest old patient with anemia, the 
finding that subjects with unexplained anemia showed no excess mortality is of great 
interest. First, we found in line with the literature that older subjects with low heamo-
globin levels are not “normal” and need further medical attention. Second, we found 




unexplained anemic people, clinicians must realize that their low hemoglobin level has 
no impact on survival. It can be hypothesized that in subjects with unexplained anemia, 
a relatively low hemoglobin level is part of their “normal” phenotype. If so, than in the 
face of ageing, do those subjects have a survival advantage due to their beneficial rheol-
ogy? Furthermore, might the unexplained anemia be caused by impaired erythrocyte 
production due to an age-associated diminished hematopoietic stem cell proliferative 
capacity or by an one lineage MDS presenting as anemia without white blood cell or 
platelet features with a very low risk of further deterioration and therefore without im-
pact on survival? If confirmed in other prospective observational studies, further clinical 
and invasive evaluation to the cause of anemia is not necessary in this very old group of 
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Met het ouder worden veranderen de fysiologische processen van het menselijk lichaam.
De veroudering van verschillende weefsels en organen gaat gepaard met een toegeno-
men kwetsbaarheid van ons lichaam. De meeste functies zijn gewoonlijk vlak voor het 
dertigste levensjaar optimaal en nemen dan langzaam maar zeker af. Maar zelfs met dit 
verlies blijft de functionaliteit van de verschillende organen tijdens de rest van het leven 
op een voldoende niveau, aangezien onze organen over aanzienlijk meer functionele 
capaciteit beschikken dan het lichaam nodig heeft (functionele reserve). Hoewel de 
afname van de functionele capaciteit van tal van organen slechts weinig invloed heeft 
op de leefwijze van de mens, kan een dergelijk verlies van grote invloed zijn op de 
gezondheid, welbevinden en ook overlevingskansen. Veranderingen in de nierfunctie 
bijvoorbeeld kunnen grote gevolgen hebben voor de mate waarin bij ouderen sommige 
geneesmiddelen uit het lichaam kunnen worden afgevoerd.
Het eerste deel van dit proefschrift richt zich op onderzoek van de veroudering van de 
nierfunctie, op de capaciteit tot het produceren door de ouder wordende nieren van het 
hormoon erythropoëtine (EPO) en de aanmaak van hemoglobine door het beenmerg 
op oude leeftijd. Het tweede deel van dit proefschrift gaat over de consequenties van de 
achteruitgang in nierfunctie en het hebben van bloedarmoede (vermindering in hemo-
globine) op oude leeftijd. Een belangrijke doelstelling voor dit onderzoek was inzicht te 
verkrijgen in de nierfunctie, erythropoëtine productie en het hemoglobine gehalte bij 
oudere mensen alsmede om te onderzoeken wat het effect van de genoemde determi-
nanten is op de overlevingskans. Het achterliggende idee is om in de klinische praktijk 
gefundeerde adviezen te kunnen geven dan wel therapieën te kunnen initiëren of juist 
na te laten bij oudere patiënten met een verminderde nierfunctie, met verminderde 
erythropoëtine productie als mede bij ouderen met bloedarmoede.
Fysiologie : hemoglobine, erythropoëtine en nierfunctie
Belangrijk voor het begrijpen van ziekten bij oudere mensen is te weten hoe de verou-
deringsprocessen van de diverse orgaansystemen verlopen. Dit is met name van belang 
omdat het aantal ouderen de komende jaren fors zal toenemen en in 2050 zal een vijfde 
van de mondiale bevolking ouder zijn dan 85 jaar. (1)
De veroudering heeft verschillende invloed op de diverse orgaansystemen. Zo blijft 
bijvoorbeeld de beenmerg functie, welke onder andere zorgt voor de aanmaak van de 
rode bloedcellen, over de jaren heen redelijk intact. (2) Bloedarmoede op oudere leeftijd 
is dan ook niet een normale bevinding. Ondanks dat de gerapporteerde prevalentie 
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van bloedarmoede bij ouderen variabel is, wordt deze geschat op 40% in de algemene 
populatie van de oudste ouderen. (3,4) Het hebben van bloedarmoede is in algemene 
zin niet gunstig en wordt op oude leeftijd geassocieerd met afname van vitaliteit, 
functionele achteruitgang, cognitieve stoornissen en verhoogde sterftekans. (5,6) Van 
een ander belangrijk orgaansysteem, de nieren, is bekend dat de functie juist lineair 
afneemt met het vorderen van de leeftijd. Chronische nierziekte, zich uitend in een ver-
minderde nierfunctie, komt veel voor op oudere leeftijd en is voorspellend voor zowel 
hart-en-vaatziekte als ook voor sterfte. (7,8) Ondanks de afname in nierfunctie lijkt het 
door de nieren geproduceerde hormoon erythropoëtine dezelfde spiegels te hebben 
op oudere leeftijd als op jonge leeftijd. EPO bevordert de vorming van rode bloedcellen 
en is recent ook, onafhankelijk van andere factoren, geassocieerd met mortaliteit op 
oude leeftijd. (9)
Voor het begrijpen en interpreteren van nierfunctie, EPO spiegels en bloedarmoede 
bij de oudere patiënt is de kennis van de gebruikelijke veroudering van deze organen 
onontbeerlijk. Ook wetenschap met betrekking tot overlevingskansen zou van waarde 
kunnen zijn bij de klinische besluitvorming bij deze oudste ouderen. Immers, bij beperk-
te overleving zal kunnen worden afgezien van belastende behandelingen van andere 
aandoeningen. Dit zal zeker bijdragen aan het welbevinden als ook aan de kwaliteit van 
zorg voor en kwaliteit van leven van (aller-) oudste patiënten.
Onderzoekspopulaties
Leiden 85-plus studie
Een belangrijk deel van het onderzoek beschreven in dit proefschrift maakt deel uit van 
de Leiden 85-plus studie. Deze studie is een longitudinaal onderzoek van een cohort 
Leidse ouderen van 85 jaar oud. Werving van deze ouderen vond plaats tussen 1997-
1999. Alle inwoners van Leiden, ook als zij woonachtig waren in een verpleeghuis, 
werden kort nadat zij 85 jaar geworden waren uitgenodigd om mee te doen aan deze 
studie. Er werd hierbij niet geselecteerd op gezondheid of demografische kenmerken.
(10) In het totaal hebben 599 ouderen deelgenomen aan dit onderzoek en dat is 87 % 
van alle potentiële deelnemers. Alle deelnemende ouderen werden thuis bezocht en 
geïnterviewd. Tenslotte werd bloed afgenomen en een electrocardiogram gemaakt. 






Voor de studie naar de associatie tussen hematologische parameters en overleving bij de 
oudste ouderen, werden de deelnemers van de Leiden Langleven studie geïncludeerd. 
In de Leiden Langleven studie namen 420 families deel, bestaande uit langlevende 
Kaukasische broers en zussen samen met hun kinderen en de partners van de kinderen. 
(11) De langlevende broers waren tenminste 89 jaar oud en de langstlevende zussen 
tenminste 91 jaar. Alle deelnemers bezochten het studiecentrum in Leiden alwaar ook 
bloed werd afgenomen.
Bronovo studie
Ter vergelijking van het hemoglobine gehalte, de EPO spiegels en nierfunctie van de 
oudste ouderen met jongere individuen werden de deelnemers van de Bronovo studie 
onderzocht. Het Bronovo cohort was eerder gebruikt om referentie waarden voor de 
verschillende bloedwaarden voor allerlei verschillende leeftijdsgroepen te bepalen. Dit 
onderzoek vond plaats in een perifeer ziekenhuis in ’s-Gravenhage. In totaal werden er 
bij 275 random geselecteerde vrijwilligers in de leeftijd van 20-85 jaar bloed afgeno-
men, waarbij er niet werd geselecteerd op gezondheid of demografische kenmerken. 
(12) Alleen zwangere personen alsmede mensen met diabetes mellitus, gebruik van 
anticonceptiva, vitamine of foliumzuur suppletie dan wel orale antistolling werden 
uitgesloten van deelname.
Leiden Heupfractuur studie
Voor het onderzoek naar het effect van de hoogte van het hemoglobine gehalte op 
de opname duur na heupchirurgie werd de Leiden Heupfractuur studie gebruikt. In 
deze studie werden 344 patiënten na acute heupchirugie bekeken die ouder waren dan 
65 jaar. Allen werden geopereerd in de periode 2005 tot 2006 in het Leids Universitair 
Medisch Centrum. Het enige exclusie criterium was patiënten met een re-operatie in 
verband met ernstige bloedingcomplicaties. Het totaal cohort bestond uit 317 ouderen. 
Hemoglobine waarden en opnameduur werden verkregen uit het patiëntinformatie 
systeem van het Leids Universitair Medisch Centrum.
Leeftijdsinvloed op nierfunctie
De glomerulaire filtratiesnelheid (GFR), het totale volume van urine wat in een gedefini-
eerde tijdseenheid gefilterd wordt door alle glomeruli van beide nieren bij mensen met 
een normale bloeddruk, is ongeveer 0,12 liter per minuut oftewel ca. 170 liter per dag. 
De GFR is de belangrijkste factor voor het inschatten van de nierfunctie. Aangezien het 
nagenoeg onuitvoerbaar is om bij de oudste ouderen de GFR te meten, bijvoorbeeld 
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door inuline toediening, is het zeer belangrijk om deze GFR adequaat te kunnen bere-
kenen. In hoofdstuk 2 wordt de studie beschreven waarin het effect van leeftijd op de 
meest gebruikte formules om de nierfunctie te berekenen is onderzocht. De resultaten 
tonen aan dat de Cockroft-Gault formule, waarin het lichaamsgewicht is geïncorporeerd 
de nierfunctie onderschat bij de oudste ouderen in vergelijking met de MDRD en de 
CKD-EPI formules. Verder werden er aanwijzingen gevonden dat met implementatie 
van de nieuwe CKD-EPI formule het aantal oude mensen met chronisch nierlijden zal 
toenemen. Op basis van deze resultaten werd geconcludeerd dat het belangrijk is om 
in de klinische praktijk de voor- en nadelen van formules die nierfunctie berekenen te 
kennen en daarop in te spelen, zeker voor de oudste groep patiënten. Het belang van 
het adequaat calculeren van de nierfunctie wordt verder ondersteund doordat deze 
studie aantoonde dat een slechte nierfunctie bij oude mensen (< 30ml/min/1.73m2) 
geassocieerd is met een verhoogd risico op overlijden. De MDRD formule voorspelt dit 
verhoogd overlijdensrisico het meest bij oude mensen. Echter meer onderzoek naar de 
meest adequate berekening voor nierfunctie voor de oudste ouderen is nodig.
Trias hemoglobine, erythropoëtine, nierfunctie en leeftijd
In hoofdstuk 3 worden de resultaten gepresenteerd van de studie naar de relatie van 
leeftijd op de spiegels van erythropoëtine en hemoglobine en de nierfunctie in ge-
zonde vrijwilligers. De onderzoekspopulatie bestond uit deelnemers van de Bronovo 
Studie in de leeftijd van 30 tot 85 jaar. Het onderzoek toonde aan dat het hemoglobine 
gehalte en het aantal erythrocyten (rode bloedcellen) stabiel blijven over de jaren heen, 
in tegenstelling tot het aantal reticulocyten (jonge, onrijpe rode bloedcellen) welke 
dalen met toename in leeftijd. Verder werd ondanks achteruit gaande nierfunctie met 
toenemende leeftijd, verhoogde erythropoëtine spiegels gevonden op oudere leeftijd. 
Twee mogelijke hypotheses ten aanzien van deze bevindingen worden beschreven. 
Kort gezegd is de meest waarschijnlijk verklaring dat het stijgen van de EPO spiegels 
de nieuwgevormde erytrocyten beschermd tegen afbraak en tevens hun overleving 
verlengd hetgeen resulteert in een stabiel aantal erythrocyten. Verder worden met het 
vorderen van de leeftijd de hematopoëtische voorloper cellen minder gevoelig voor 
erythropoëtine wat resulteert in een verminderd aantal reticulocyten. De hierdoor 
dreigende anemie leidt tot een stijging van de EPO productie. 
De tweede hypothese is dat er primair een stijging van de EPO spiegel plaats vindt 
ten gevolge van lokale hypoxie in de nier door verminderderde nierdoorbloeding 
ten gevolge van arteriosclerose op oude leeftijd. Door de erythropoëtine geïndu-




bloedcellen geremd worden om een stabiel aantal te bereiken. Het is van belang dat 
verder onderzoek gaat plaatsvinden naar het onderliggend mechanisme achter het ge-
lijk blijven van het hemoglobine gehalte en het aantal erythrocyten op oudere leeftijd 
ondanks de stijging van het erythropoëtine.
Hematologische parameters bij oudste ouderen
De studie waarin gekeken wordt of bij ouderen met familiaire langlevendheid dit over-
levingsvoordeel deels toegeschreven kan worden door toegenomen hematopoëtische 
(beenmerg) capaciteit staat beschreven in hoofdstuk 4. Het onderzoek toonde aan dat 
ouderen met familiare langlevendheid inderdaad een overlevingsvoordeel hebben, 
maar dat er geen verschillen waren in aantallen leucocyten, thrombocyten en het 
hemoglobine gehalte in vergelijking met gewone ouderen. Derhalve kan de verklaring 
van de langlevendheid niet gezocht worden in de hematopoëtische capaciteit. Verder 
bleek dat alle ouderen met familiaire langlevendheid met bloedarmoede een hoger 
overlijdensrisico hadden dan dezelfde ouderen zonder anemie. Geen relatie werd 
gevonden met lage aantallen witte bloedcellen en bloedplaatjes en overlevingskans in 
ouderen met familiaire langlevendheid. Gezien de verlaagde overlevingskans verdient 
het aanbeveling om bloedarmoede niet toe te schrijven aan leeftijd maar om verder 
onderzoek in te stellen naar de oorzaak van het ontstaan van de anemie. Meer studie in 
families met exceptionele langlevendheid en hematologische veranderingen is uiter-
aard nodig.
Onafhankelijke voorspellers van mortaliteit
De resultaten van de studie ten aanzien van de voorspellende waarden van witte 
bloed cellen en C-reactive protein (CRP) bij de oudste ouderen worden beschreven in 
hoofdstuk 5. Verhoogde waarden van witte bloedcellen en CRP is op middelbare leeftijd 
geassocieerd met een verhoogd risico op ziekte en sterftekans.(13-15) Deze studie laat 
zien dat ook bij de oudste ouderen zowel CRP als ook witte bloedcellen onafhankelijke 
voorspellers zijn voor sterfte. Het is onwaarschijnlijk dat onderliggende ziekten bij de 
start van de studie hieraan hebben bij gedragen, aangezien de resultaten hetzelfde 
bleven na correctie voor co-morbiditeit. 
De pathofysiologische verklaring waarom verhoogde aantallen witte bloedcellen sterfte 
voorspellen is niet goed begrepen. Zijn deze verhoogde witte bloedcellen direct betrok-
ken bij het ontstaan van vasculaire aandoeningen dan wel zijn deze witte bloedcellen 
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meer een risico indicator voor andere factoren die vasculaire schade veroorzaken? (16) 
Meer onderzoek naar het pathofysiologische mechanisme achter de verhoogde aantal-
len witte bloedcellen en hun rol bij de verhoging van de mortaliteit zou meer helderheid 
hierover kunnen opleveren. In de klinische praktijk lijkt het aan te bevelen om meer 
aandacht te besteden aan de potentie van witte bloedcellen als voorspeller van sterfte 
bij de oudste patiëntengroep.
Onverklaarde anemie en overlevingskans
In hoofdstuk 6 wordt de associatie tussen onverklaarde bloedarmoede en overleving 
beschreven. De resultaten laten zien dat bij onze oudste ouderen (85 jaar) in 37% van 
de mensen geen medische verklaring voor hun bloedarmoede werd gevonden. Deze 
relatieve hoge prevalentie van personen met onverklaarde bloedarmoede betekent 
dat onder een belangrijk deel van de oudere bevolking geen verklaring gevonden 
wordt voor hun bloedarmoede. Verder werd geconcludeerd dat de mensen met deze 
onverklaarde bloedarmoede gelijke overlevingskansen hadden in vergelijking met 
mensen zonder bloedarmoede. Deze resultaten zouden kunnen betekenen dat als bij 
oudere patiënten geen oorzaak voor de bloedarmoede kan worden gevonden, geen 
verregaande klinische onderzoeken hoeven plaats te vinden. Uiteraard zal deze bevin-
ding verder onderzocht moeten worden, bij voorkeur in prospectieve observationele 
studies als ook in interventie studies. Overigens werd een twee keer zo hoog risco op 
overlijden gevonden in de groep ouderen met een bloedarmoede waarvoor wel een 
verklaring was gevonden in vergelijking met de ouderen zonder bloedarmoede en die-
gene met onverklaarde bloedarmoede. Het lijkt evident dat op basis van bovenstaande 
bevindingen verder onderzoek noodzakelijk is naar de implicaties van de onverklaarde 
bloedarmoede bij ouderen met als doel het aantal ziekenhuis bezoeken en belastende 
onderzoeken tot een minimum te beperken.
Hemoglobine voorspelt opnameduur na heupfractuur operatie
Bloedarmoede en heupfracturen zijn beiden veel voorkomende aandoeningen bij 
oudere mensen. De relatie tussen bloedarmoede en een heupoperatie vanwege een 
gebroken heup is controversieel. De voorspellende waarde van het hemoglobine 
gehalte rondom een heupoperatie werd onderzocht in een historisch cohort van ou-
dere patiënten met een gebroken heup die in het Leids Universitair Medisch Centrum 
geopereerd werden en de resultaten zijn beschreven in hoofdstuk 7. Het hemoglobine 




duur in het ziekenhuis na een heupoperatie, terwijl het uitgangs-hemoglobine gehalte 
van voor de operatie geen enkele invloed heeft op de opname duur. Deze resultaten 
zouden kunnen betekenen dat bij oudere patiënten met acuut ontstane bloedarmoede 
ten gevolge van het bloedverlies bij de heupoperatie dit een negatieve invloed heeft op 
het post-operative beloop en herstel van deze ouderen. Aangezien er heden ten dage 
een strenge transfusie richtlijn geldt in ons land voor alle leeftijden, zou, indien onze 
resultaten worden bevestigd in grotere, prospectieve onderzoeken, de huidige richtlijn 
wat betreft ouderen moeten worden aangepast.
Conclusies en toekomstig onderzoek
Kennis met betrekking tot de fysiologische veranderingen door veroudering van de 
nierfunctie, EPO en het hemoglobine gehalte is essentieel voor klinici. De resultaten van 
de hier beschreven onderzoeken geven inzicht in de leeftijdgerelateerde verandering in 
nierfunctie en de relatie met erythropoëtine productie alsmede het handhaven van de 
hemoglobine spiegels op oudere leeftijd. Voorts kan er op basis van deze bevindingen 
gespeculeerd worden over de voorspellende waarde op overlevingskansen van de mar-
kers nierfunctie, EPO en hemoglobine bij de oudste ouderen. Het belang van deze ken-
nis is een toegenomen alertheid onder medici op een verhoogd overlijdensrisico voor 
deze oudere personen. Verder kan deze kennis bijdragen aan de zogeheten “tailor made 
medicine” wat wil zeggen een behandelingsprogramma op het individu toegesneden.
Drie fenomenen bij de oudste ouderen die in dit proefschrift beschreven zijn verdienen 
in het bijzonder de aandacht voor toekomstig onderzoek: de meest adequate manier 
om de nierfunctie te berekenen, de waarde van EPO en de rol van onverklaarde anemie.
Het begrijpen van de tekortkomingen van de verschillende formules om de nierfunctie 
te berekenen op hogere leeftijd is een uitdaging. De MDRD formule lijkt de beste schat-
ting te geven voor de oudste ouderen, terwijl het toepassen van de nieuwe CKD-EPI 
formule ten opzichte van de MDRD formule leidt tot een toename van het aantal oude-
ren met chronische nierinsufficiëntie, hetgeen consequenties heeft voor therapeutische 
besluitvorming en het aantal ziekenhuisopnames. Daarnaast kan een toename in ver-
wijzingen van deze oudste ouderen naar de nefroloog leiden tot andere dilemma’s. Het 
nut van een nierbiopsie of van nierfunctievervangende therapie bij deze patiënten met 
comorbiditeit moet opwegen tegen de complicaties. De eventuele meerwaarde ervan 
op de kwaliteit van leven moet hierin leidend zijn.
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EPO spiegels in oudere individuen blijken relatief laag indien er sprake is van ernstig 
nierfalen (< 30ml/min/1.73m2). Meer onderzoek is noodzakelijk om deze resultaten te 
bevestigen in andere populaties oudere patiënten. Indien dit het geval zou zijn, kan bij 
ouderen met ernstige nierfunctiestoornis, erythropoëtine substitutie therapie overwo-
gen worden, wat haar waarde al heeft bewezen in het verbeteren van de kwaliteit van 
leven bij predialyse- en kankerpatiënten.
In lijn met de literatuur wijst ons onderzoek ook uit dat anemie bij ouderen niet “nor-
maal” is en daarom ook aandacht verdient. In de benadering van de oudste ouderen 
met bloedarmoede is het belangrijk om te realiseren dat onverklaarde anemie niet is 
geassocieerd met meer sterfte. Theoretisch zou het zo kunnen zijn dat in deze groep 
patiënten met onverklaarde anemie, een relatief laag hemoglobine gehalte onderdeel 
is van hun “normale” fenotype. Hiervan uitgaande hebben deze mensen, in het licht van 
veroudering, wellicht een overlevingsvoordeel ten gevolge van hun gunstige reologie?
Anderszins zou een onverklaarde anemie veroorzaakt kunnen worden door afgenomen 
erytrocyten productie ten gevolge van leeftijd gerelateerde capaciteitsafname van de 
haematopoëtische stamcel. Een myelodysplastisch syndroom (MDS) waarbij slechts een 
cellijn uitvalt (de erytrocyten) met hierbij een laag risico op verdere verslechtering van 
het ziektebeeld, kan ook een onverklaarde anemie zonder overlevingsnadeel verklaren. 
Als één van bovenstaande hypotheses in verder prospectief observationeel onderzoek 
bevestigd wordt, zal het in de toekomst niet meer nodig hoeven zijn om de oudste ou-
deren met onverklaarde anemie bloot te stellen aan klinische en/of invasieve evaluatie.
Uiteraard zal er naast verder onderzoek, blijvend aandacht besteed moeten worden om 
de vertaalslag tussen wetenschappelijk onderzoek en de dagelijkse klinische praktijk te 






 (1) World Population Ageing: 1950-2050.23 p. New York United Nations Populations. 2002. Report
 (2) Baldwin JG, Jr. Hematopoietic function in the elderly. Arch Intern Med 1988; 148(12): 2544-6.
 (3) Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 
65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 
2004; 104(8): 2263-8.
 (4) Izaks GJ, Westendorp RG, Knook DL. The definition of anemia in older persons. JAMA 1999; 
281(18): 1714-7.
 (5) Culleton BF, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Hemmelgarn BR. Impact of anemia on 
hospitalization and mortality in older adults. Blood 2006; 107(10): 3841-6.
 (6) Penninx BW, Guralnik JM, Onder G, Ferrucci L, Wallace RB, Pahor M. Anemia and decline in physi-
cal performance among older persons. Am J Med 2003; 115(2): 104-10.
 (7) Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, 
cardiovascular events, and hospitalization. N Engl J Med 2004; 351(13): 1296-305.
 (8) Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M et al. Chronic kidney disease and mortal-
ity risk: a systematic review. J Am Soc Nephrol 2006; 17(7): 2034-47.
 (9) den Elzen WP, Willems JM, Westendorp RG, de Craen AJ, Blauw GJ, Ferrucci L et al. Effect of eryth-
ropoietin levels on mortality in old age: the Leiden 85-plus Study. CMAJ 2010.
 (10) der Wiel AB, van EE, de Craen AJ, Gussekloo J, Lagaay AM, Knook DL, Westendorp RG. A high 
response is not essential to prevent selection bias: results from the Leiden 85-plus study. J Clin 
Epidemiol 2002; 55(11): 1119-25.
 (11) Westendorp RG, van Heemst D, Rozing MP, Frolich M, Mooijaart SP, Blauw GJ et al. Nonagenarian 
siblings and their offspring display lower risk of mortality and morbidity than sporadic nonage-
narians: The Leiden Longevity Study. J Am Geriatr Soc 2009; 57(9): 1634-7.
 (12) Steen G, Vlasveld LT, Poot CC, van der Slot-Verhoeven AJ, Castel A. Onderzoek naar referen-
tiewaarden van laboratoriumonderzoek in een algemeen ziekenhuis: resultaten en bevindingen. 
Ned Tijdschr Klin Chem Labgeneesk 2008; 34 (1): 35-43.
 (13) de Labry LO, Campion EW, Glynn RJ, Vokonas PS. White blood cell count as a predictor of mortal-
ity: results over 18 years from the Normative Aging Study. J Clin Epidemiol 1990; 43(2): 153-7.
 (14) Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease. Insights 
from the Framingham Study. JAMA 1992; 267(9): 1253-6.
 (15) Margolis KL, Manson JE, Greenland P, Rodabough RJ, Bray PF, Safford M et al. Leukocyte count as a 
predictor of cardiovascular events and mortality in postmenopausal women: the Women’s Health 
Initiative Observational Study. Arch Intern Med 2005; 165(5): 500-8.









JM Willems, S Trompet, EP Slagboom, AJM de Craen, RGJ Westendorp. Hematopoietic 
capacity and exceptional survival. The Leiden Longevity Study. J Am Geriatr Soc. 2008 
Nov; 56(11): 2009-13.
GM Alkemade, JM Willems. Polycytemia vera presenting as sudden onset cognitive 
impairment. J Am Geriatr Soc. 2008 Dec; 56(12): 2362-236.
WPJ den Elzen, JM Willems, RGJ Westendorp, AJM de Craen, WJJ Assendelft, J Gussekloo. 
Effect of anemia and comorbidity on functional status and mortality in old age: results 
from the Leiden 85-plus Study. CMAJ. 2009 Aug 4; 181(3-4): 151-7.
FJ Vogelaar, HM Schuttevaer, JM Willems. A patient with an inguinal mass: a groin her-
nia? Neth J Med 2009 Dec; 67(11): 399-400.
JM Willems, S Trompet, GJ Blauw, RGJ Westendorp, AJM de Craen. White blood cell 
count and C-reactive protein are independent predictors of mortality in the oldest old. J 
Gerontol A Biol Sci Med Sci. 2010 Jul; 65(7): 764-8.
FJ Vogelaar, JM Willems. Plaveiselcel carcinoom als zeldzame complicatie van een hy-
dradenitis suppurativa. Ned Tijdschr Geneeskd. 2010; 154(14): A1137.
DW Maas, RGJ Westendorp, JM Willems, AJM de Craen, RC van der Mast. TNF-alfa antag-
onist infliximab in the treatment of depression in older adults: results of a prematurely 
ended, randomized, placebo-controlled trial. J Clin Psychopharmacol. 2010 Jun; 30(3): 
343-5.
WPJ den Elzen, J Gussekloo, JM Willems, AJM de Craen, GJ Blauw, WJJ Assendelft, RGJ 
Westendorp. Predictive value of low ferritin in older persons with anemia with and with-
out inflammation: the Leiden 85-plus Study. J Am Geriatr Soc. 2010 Aug; 58 (8): 1601-3.
WPJ den Elzen, JM Willems, RGJ Westendorp, AJM de Craen, GJ Blauw, L Ferrucci, WJJ As-
sendelft, J Gussekloo. Effect of erythropoietin levels on mortality in old age: the Leiden 
85-plus Study. CMAJ. 2010 Dec 14; 182(18): 1953-8.
118
Publicaties
W van de Water, FJ Vogelaar, JM Willems. An unusual complication four years after 
laparoscopic adjustable banding: jejunal obstruction due to the connecting tube. Obes 
Surg. 2011 Jan; 21(1): 131-3.
JM Willems, WPJ den Elzen, LT Vlasveld, RGJ Westendorp, J Gussekloo, AJM de Craen, GJ 
Blauw. No increased mortality risk in older persons with unexplained anemia. Age and 
Ageing. 2012 Jul; 41(4): 501-6.
JM Willems, AJM de Craen, RGGH Nelissen, PA van Luijt, RGJ Westendorp, GJ Blauw. 
Haemoglobin predicts length of hospital stay after hip fracture surgery in older patients. 
Maturitas. 2012 Jul; 72(3): 225-8.
JM Willems, LT Vlasveld, WPJ den Elzen, RGJ Westendorp, TJ Rabelink, AJM de Craen, 
GJ Blauw. Performance of Cockroft-Gault, MDRD, and CKD-EPI in estimating prevalence 





Vele ouderen, vrijwilligers en patiënten hebben bijgedragen aan de totstandkoming van 
dit proefschrift. Hun belangeloze bereidwilligheid om mee te werken aan de voortgang 
van de medische wetenschap op het gebied van de veroudering is fantastisch!
Daarnaast mijn welgemeende waardering voor allen die betrokken waren bij de opzet 
en uitvoering van de studies en alle andere (oud-)medewerkers van de afdeling Oude-
ren-geneeskunde van het LUMC. Rudi Westendorp gaf mij de kans om dit onderzoek 
te initiëren en heeft samen met Gerard Jan Blauw en Ton de Craen, keer op keer de 
prikkel gegeven vanuit zowel een klinisch alsook epidemiologisch gezichtspunt, om dit 
onderzoek een slag verder te brengen. Tezamen met mijn paranimfen, Stella Trompet en 
Joep Lagro, heb ik leerzame, constructieve en tevens ook gezellige momenten gedeeld 
zowel binnen als ook buiten het ziekenhuis.
Een bijzonder woord wil ik richten aan mijn ouders, zeer verheugd zijnde dat beiden 
nog getuige kunnen zijn van mijn promotie; lieve pap en mam, het gevoel dat jullie 
altijd onvoorwaardelijk achter me staan en immer mijn lieve en trotse supporters zijn, is 
voor mij zeer waardevol.
En tot slot het onontbeerlijke thuisfront; lieve Jelle en Carlijn, wat een geluk om zulke 
fantastische kinderen te hebben. Ik ben zeer trots op jullie allebei!
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